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AIM OF THE STUDY  
 
Heart failure (HF), which is the end-stage of pathological cardiac hypertrophy, is a leading cause 
of hospitalization and mortality. Cardiac remodeling, hypertrophy and fibrosis characterize HF. 
These pathological hallmarks are accompanied by systemic inflammatory response and immune 
cell infiltration and activation. As clinical trials targeting pro-inflammatory cytokines in HF were 
unsuccessful, possibly due to redundant functions of individual cytokines, we attempted to better 
target cardiac inflammation in order to develop an immunotherapy for HF. 
Characterizing the inflammatory response in the myocardium of the gold-standard mouse model 
of HF, as well as in biopsies of patients with different forms of HF, we were able to link T cells 
with the progression of HF. As T cells are responsible for chronic and lost-lasting immune 
responses we decided to use them as therapeutic target. To do so we blocked T cell costimulation 
through FDA-approved rheumatoid arthritis drug CTLA-4Ig (abatacept, BMS). The therapeutic 
effects obtained with the administration of abatacept enforced the hypothesis that T cells are 
involved in the pathogenesis of HF thus electing them as potentially relevant therapeutic target 
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INTRODUCTION 
 
Note to the reader: 
This thesis describes an immunological study of cardiac pathology. In order for the reader to 
follow the work discussed, it was deemed useful to include, in the introduction, a substantial 
segment introducing basic concepts of cardiac pathology. 
 
Part 1 – Characteristics and definitions of cardiac hypertrophy and heart failure 
 
1.1 Brief overview of cardiac anatomy and physiology 
 
The primary energetic source of eukaryotic cells is the oxidative metabolism of glucose.  
Approximately 90% of the oxygen intake in eukaryotic organisms is utilized through oxidative 
phosphorylation (Taylor et al., 2007).  
In order to distribute oxygen to all their cells, multicellular organisms have evolved 
cardiovascular systems. The cardiovascular system (from Kardia [heart] + vasculum [small 
vessel, pod]) is composed of the heart and blood vessels. The heart is a hollow muscular organ 
that acts as a pump allowing the circulation of a fluid, the blood, through a web of tubes that are 
the vessels. The muscular tissue composing the heart is the involuntary striated muscle; it is 
formed by sarcomeres, which are its component contractile units. Sarcomeres are, in turn, 
constituted by filaments of actin and myosin. Actin and myosin create, respectively, the thin and 
thick filaments. During contraction, the thin and thick filaments, that normally overlap, slide on 
each other, shortening the entire fiber. 
Macroscopically, the heart is composed of four chambers separated by 4 valves: right atrium, 
right ventricle, left atrium and left ventricle, separated in the center by the septum. The valves 
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open and close in response to changes of pressure that occur during a cardiac cycle; in this way 
the direction of blood flow through the 4 chambers is controlled. The valves between the 
ventricles and the atria are called atrial-ventricular valves (AV valves) and the valve between the 
ventricle and the arteries are called semilunar valves.  
The right atrium receives blood from peripheral tissues that subsequently pass to the right 
ventricle, enter the pulmonary circulation through the pulmonary artery, and thus reach the 
lungs. Once it arrives in the lungs, the blood uptakes oxygen and releases carbon dioxide. It then 
moves into the left atrium and the left ventricle, before leaving the heart through the aorta, to 
replenish with oxygen all the peripheral tissues.  
In the duration of one heartbeat, the heart completes a cardiac cycle, which includes systole and 
diastole. The systole refers to the contraction phase of the myocardium, whilst the diastole is the 
phase during which the myocardium is relaxed. Since blood flow follows a pressure gradient 
from a low-pressure area to a high-pressure area, the contraction of the myocardium increases 
the pressure. The cardiac cycle is composed of 5 phases: 
1- atrial and ventricular diastole; the atria are relaxed and receive blood from the veins 
whilst the ventricles have just ended the contraction phase. As long as the ventricles 
relax, the valves between atria and ventricles open and let the blood flow in the 
ventricles. 
2- Atrial systole; although the majority of the blood enters the ventricles passively thanks to 
atrial relaxation, an extra 20% enters in consequence of atrial contraction (atrial systole). 
3- Isovolumic ventricular contraction; this is the beginning of ventricular contraction 
(systole). The muscles start to contract from the heart apex (the lower end of the heart), 
the pressure inside the chamber rises and the AV valves close. The muscular fibers of the 
atria start to relax.  
4- Ventricular ejection; the ventricles’ contraction generates a pressure inside the chamber 
sufficiently high to open the semilunar valves. The blood is ejected into the arteries; the 
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high pressure of the blood freshly ejected from the ventricles makes the blood already 
present in the vessels move. 
5- Isovolumic ventricular relaxation; at the end of the ventricular ejection, the ventricles 
start to relax and the pressure in the ventricles falls, blood flows back and this imposes 
the closure of the semilunar valves. When the ventricular pressure is lower then the atrial 
pressure, AV valves open and the blood accumulated inside the atria during the 
ventricular contraction fills the ventricles, so that a new cardiac cycle can start 
(Silverthorn, 2007). 
 
1.2 Definition of cardiac hypertrophy 
 
“Hypertrophy” (noun) derives from the Greek words hyper (above) and trophe (nutrition); in 
medical terminology it is commonly used to indicate the enlargement of an organ in consequence 
of the increased size of its own cells (Berenji et al., 2005). The term hypertrophy, as applied to 
cardiology, comprises numerous pathophysiological conditions in which, in response to different 
stimuli, a cardiac enlargement occurs (Dorn et al. 2003). Cardiac enlargement is an adaptive and 
compensatory mechanism of the myocardium to overcome increased demands of cardiac work 
and reduce ventricular wall tension in response to stimuli of different origin (Hunter and Chien, 
1999; Samak et al., 2016). In the late 19th century the Swedish physician S. Henschen first 
discovered, in cross-country skiers, that excessive exercise causes an enlargement of the heart 
accompanied by what must be inferred to be improved heart functionality. Henschen defined this 
condition as “athlete’s heart” (Rost, 1997; Forteza-Alberti et al., 2016). 
Indeed we now know that cardiac enlargement is considered physiological when it develops 
during exercise training, development and pregnancy; in these cases it is a mild and/or reversible 
condition characterized by increased maximal cardiac output and stroke volume, decreased 
resting heart rate and electrocardiographic changes in conduction (Mihl et al., 2008; Berenji et 
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al., 2005). In the same period as Henschen, Sir William Osler observed that cardiac hypertrophy 
can evolve from adaptive to maladaptive. Osler identified cardiac hypertrophy as the base of the 
development of heart failure. Whilst athlete’s heart is characterized by increased heart 
functionality, heart failure was thus associated with decreased heart functionality. More 
specifically, it was linked to a reduction in the function of the cardiac ventricles (Forteza-Alberti 
et al., 2016). Although the hypertrophic cardiac growth is a compensatory adaptation of the 
myocardium in order to overcome the increased workload, in presence of chronic stimuli 
myocardium remodeling is irreversible.  The presence of excessively increased ventricular 
dimensions and reduced ventricular functionality distinguish pathological cardiac growth from 
physiological hypertrophy.  Eventually the myocardium pump function, which is the main means 
of the organisms to provide oxygen to peripheral tissues, is too compromised and heart failure 
develops (Grossman et al., 1975; Samak et al., 2016).  
Thus, in current clinical practice, cardiac hypertrophy is classified as:  
• concentric remodeling, characterized by normal cardiac mass with increased relative wall 
thickness  
• concentric hypertrophy, when there is an increase in both relative wall thickness and 
cardiac mass with no changes or decrease in the chamber dimension; this is associated 
with increased cardiac afterload as consequence of aortic stenosis or hypertension 
(Gjesdal et al., 2011) 
• eccentric hypertrophy, which typically evolves from increased preload conditions i.e. 
valvular insufficiencies, presents increased cardiac mass as well as chamber dimension 
whilst relative wall thickness may be normal, decreased, or increased. Developmental 
and physiological hypertrophies are also included in this category (Heineke and 
Molkentin, 2006; Berenji et al. 2005; Gjesdal et al., 2011).  
Concentric and eccentric hypertrophy can be anatomically distinguished according to the 
orientation of newly added sarcomeres. In concentric hypertrophy sarcomeres are added in 
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parallel and cell growth occurs in width rather than in length. On the other hand, in eccentric 
hypertrophy sarcomeres are added in series to lengthen the cell. Sarcomeres are also added in 
series when pathological cardiac hypertrophy produces a cardiac dilation phenotype with 
eccentric hypertrophy and dilatory cardiac growth (Heineke and Molkentin, 2006; Gjesdal et al., 
2011). The different cardiac hypertrophies can also be classified according to the type of 
hemodynamic stress that the myocardium undergoes: “volume-overload” usually triggers an 
eccentric hypertrophy whilst “pressure-overload” is more typical of concentric hypertrophy 
(Dorn et al., 2003; Grossman and Paulus, 2013). 
 
1.3 Characteristics of physiological cardiac hypertrophy 
 
As outlined above, physiological cardiac hypertrophy is an adaptive response to increased 
demands of blood and oxygen. To satisfy the augmented needs of the body the heart increases in 
size and often also in functionality (Shimizu and Minamino, 2016; Kemi et al., 2008; Kong et al., 
2005). During the development from early age to adulthood, there is a 3-fold increase of 
cardiomyocyte diameter in human hearts. The increase of heart weight during this period is 
almost exclusively attributed to cardiomyocyte enlargement; heart weight and body weight are 
inherently connected (Shimizu and Minamino, 2016). 
The mechanisms that activate an adaptive or a maladaptive phenotype of cardiac hypertrophy are 
still unknown. Considering that the physiological stress stimuli are usually discontinuous it is 
possible that the chronicity of the stimulus could be critical for the development towards 
physiological or pathological hypertrophic response (Perrino et al., 2006). Studies on animal 
models showed that intermittent pressure overload induces a milder hypertrophic response 
compared to chronic persistence of the stimulus; the same results were obtained when physical 
training was applied in order to induce physiological hypertrophy. Thus the cardiac hypertrophy 
phenotype, pathological or physiological, is depending on the nature of the stress signal, 
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respectively pressure-overload versus exercise training, whilst the duration is responsible for the 
severity (Perrino et al., 2006). 
Studies on gene expression in rat models show that there is differential gene activation according 
to the hypertrophy phenotype. For instance in physiological hypertrophy there is an increased 
expression of genes involved in cell growth and metabolism, whilst on the other hand in 
pathological conditions there is an increased expression of genes involved in the oxidative stress 
response (Kong et al., 2005). 
  
1.3.1 Molecular pathways involved in physiological hypertrophy 
 
Cardiac remodeling in physiological hypertrophy differs from pathological hypertrophy also in 
the absence of fibrosis. This makes physiological hypertrophy a harmless and reversible 
condition. Physiological hypertrophy progresses via growth hormone signals and mechanical 
forces. Growth hormones, including thyroid hormone and insulin-like growth factor-1 (IGF-1), 
activate signaling pathways throughout phosphoinositide 3-kinase (PI3K), AMP-activated 
protein kinase (AKT) and mammalian target of rapamycin (mTOR). Signal transduction of these 
pathways induces cardiac growth (Shimizu and Minamino, 2016). IGF-1 has short-term insulin-
like effects and long-term growth-factor effects on cell metabolism. IGF-1 activity is mediated 
via the binding of IGF-1 receptor; IGF-1 receptor phosphorylates the insulin receptor substrate 
(IRS-1 and IRS-2) initiating the intracellular signal transduction. The IGF-1 signal activates 
MAP kinases that trigger transcription factor activity. The effects of IGF-1 signaling in the 
myocardium include increased DNA and protein synthesis, reduced protein degradation and anti-
apoptotic effects. IGF-1 has rapid and long-lasting effects on the cardiac tissue; in normal 
conditions in rat hearts this signaling improves heart functionality (Ren et al., 1999). 
Overexpression of IGF receptor-1 in transgenic mice induces cardiac enlargement as a 
consequence of an increase cardiomyocyte size and increased ventricular function. This response 
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was PI3K-dependent and resembles the physiological cardiac hypertrophic response (McMullen	  
et al., 2004). Besides IGF-1 signaling, Akt/mTOR pathway is also activated in the heart during 
the response to training. The pathway is deactivated in pathological hypertrophy. Thus the 
Akt/mTOR pathway may have a key role in the differentiation between the two phenotypic 
hypertrophic responses (Kemi	  et al., 2008). Akt is a serine-threonine kinase activated by PI3K, 
which is activated through ligation of transmembrane receptors (including IGF-1). After 
activation PI3K generates phosphatidylinositol 3,4 bisphosphate (PI3,4P) and 
phosphatidylinositol 3,4,5 triphosphate (PI3,4,5P). Phospholipids generated from PI3K 
activation directly bind Akt and recruit it from the cytoplasm to the cell membrane; at this point 
Akt can be phosphorylated and fully activated. Activated Akt has anti-apoptotic effects and 
protects cardiomyocytes from cell death both in in-vivo ischemia-reperfusion models and in in-
vitro cultured myocytes in serum-deprivation conditions (Fujio	  et al., 2000). Akt involvement in 
cardiomyocyte growth in physiological hypertrophy has been demonstrated in a transgenic 
mouse model overexpressing a constitutively cardio-specific active form of Akt (E40K mutant 
Akt). Transgenic Akt (Akt-tg) mice develop heart hypertrophy with increased myocardial mass 
and ameliorated heart functionality and contractility (Condorelli et al., 2002). 
 
1.4 Pathological cardiac hypertrophy  
 
1.4.1 Causes and types 
 
Pathological cardiac hypertrophy will eventually lead to dilated cardiomyopathy (DCM); the 
final stage of the latter is heart failure. Heart failure occurs when the myocardium loses the 
capability to satisfy systemic blood and oxygen demands (Heineke and Molkentin, 2006). The 
causes of heart failure are several and different nature; according to the mechanisms that drive 
the development of HF, they can be classified in 4 categories. The first category includes both 
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traditional risk factors, such as hypertension and ischemic injury after myocardial infarction, 
coronary artery disease and metabolic syndrome, including diabetes mellitus, hyperlipidemia and 
obesity. The second category includes all the genetic alterations and congenital defects. Third are 
mechanical causes due to valve disorders, the most common of which is aortic stenosis. Aortic 
stenosis will induce a pressure-overload stress that initially induces cardiac hypertrophy and at 
the end progresses into left ventricle dysfunction. All these 3 categories are not immune-
mediated but activate an inflammatory response after an initial insult. The last category of heart 
failure causes includes the immune-mediated factors: viral or bacterial infections or autoimmune 
responses (Dick and Epelman, 2016). General symptoms of heart failure are palpitations, 
dyspnea, fatigue, confusion, appetite loss, chronic wheezing and coughing (Latronico et al., 
2008).  
Patients with HF are classified according to their heart functionality; HF can be defined as HF 
with reduced left ventricle ejection fraction (HFrEF) whilst patients with preserved EF are 
classified as suffering from HFpEF. HFrEF and HFpEF patients have similar degree of cardiac 
impairment in terms of inability to fulfill the blood supply needs of the organism (Van Tassell et 
al., 2014). 
As mentioned above for physiological hypertrophy, hypertrophic growth signals alter gene 
expression, increase protein synthesis and block protein degradation but -conversely to 
physiological conditions- compensatory mechanisms will lead to cardiomyocyte loss and 
secondary heart damage (Heineke and Molkentin, 2006; Latronico	   et al., 2008). Causes and 
effects of pathological cardiac hypertrophy are summarized in Figure A.  
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2
Figure A: Summary of the causes of HF and its pathological hallmarks. Chronic stimuli, including risk factors, 
mechanical stress, genetic alterations and infections, drive the development of HF. In pathological conditions cardiac 
hypertrophy is mediated by activation of specific molecular pathways  (MAPK, AKT, JAK/STAT) and induces increase 
protein synthesis. In parallel fetal genes are re-expressed and cardiomyocyte metabolism switches from oxidative to 
glycolytic. Fibroblasts are activated and induce production o collagen therefore formation of fibrosis. Cardiac stress 
induces also production of pro-inflammatory cytokines and expansion of macrophages. These pathological hallmarks 
together with cardiomyocyte apoptosis and autophagy lead to impaired heart functionality and HF. 
1
F
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1.4.2 Molecular pathways involved in pathological hypertrophy  
 
Pathological cardiac hypertrophy, besides showing alterated protein synthesis and gene 
expression, is characterized by cardiomyocyte metabolic changes and alterated calcium handling, 
cardiomyocyte apoptosis and autophagy as well as fibrosis formation in the myocardium and 
angiogenesis (Latronico	  et al., 2008; Tham, et al., 2015).   
The most well-studied mediators of cardiac hypertrophy are MAPK (mitogen-activated protein 
kinase), NFAT (calcineruin-nuclear factor of T cells) and IGF-1-phosphatidylinositol 3-kinase 
(PI3K)-AKT. IGF-1 signaling is mostly associated with physiological cardiac hypertrophy, 
although it has been reported that activation of this pathway is present in the initial compensatory 
phase of pathological cardiac hypertrophy (Tham et al., 2015).  
One of the main molecular pathways that induce HF progression goes through G-protein-coupled 
receptors (GPCR)-activating molecules such as thyroid hormones, angiotensin-II (AngII), 
endothellin-1 (ET-1) and α-adrenergic agonists (e.g., noradrenaline). Elevation of calcium ions 
(Ca+2) downstream of Gαq/α11 subunit activates calmodulim (Cam) that can binds to NFAT, 
inducing its translocation into the nucleus and activation of the expression of hypertrophic genes 
(Tham et al., 2015; Samak et al., 2016). Activation of Gαq/α11 can also induce activating signals 
on MAPK pathways with downstream activation of p38, JNKs and ERKs. MAPK signaling 
promotes the gene expression of hypertrophic genes (Heineke and Molkentin, 2006). 
Further, activation of Janus Kinase signal transducer and activator of transcription (JAK/STAT) 
has different effects on cardiac hypertrophy. Activation of the JAK/STAT pathway initially, in 
acute phase, promotes anti-apoptotic pathway but its chronic activation promotes inflammation 
and oxidative stress (Terrell et al., 2006; Shi and Wei, 2012).  
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1.4.3 Hypertrophic genes  
 
The increase in size of cardiomyocytes is accompanied by an altered gene expression similar to 
that observed during fetal cardiac development; for this reason this characteristic feature of 
pathological hypertrophy is defined as a reactivation of fetal gene programs. This altered gene 
expression is considered, both in humans and in animal models, causative of the maladaptive 
phenotype development (Dorn	   et al., 2003; Samak	   et al., 2016; Dirkx et al., 2013). The fetal 
genes that are reexpressed during HF are involved in different cellular pathways: contractility, 
calcium handling and cellular metabolism (Dirkx	   et al., 2013). Contractile protein cardiac 
myosin heavy chain-alpha (MHC-α), which is the adult predominant isoform, is substituted by 
myosin heavy chain-beta (MHC-β) and skeletal α-actin (SkA), which are both fetal isoforms. 
Indeed SkA is one of the principal components of adult skeletal thin muscles and the actin 
isoform of fetal heart. Normally the fetal isoforms of contractile proteins decrease after birth, in 
particular the gene encoding for SkA in healthy adult myocardium is completely silenced. In 
ventricles of mouse models of HF, the ratio α- to β-MHC is reduced and SkA expression is 
increased. Similarly to SkA, smooth muscle α-actin (αSMA), the principal actin isoform of the 
vascular and respiratory systems, is expressed in fetal heart and absent in adult cardiomyocytes. 
Ventricular expression of αSMA can be induced by hypertrophic stimuli.  (Samak et al., 2016; 
Kuwahara	  et al., 2012; Dorn et al., 2003) Atrial and brain natriuretic peptide (ANP and BNP) are 
two peptides that mediate vasodilation, inhibition of renin and are anti-mitogenic; both these 
peptides are increased at mRNA and protein levels and can be used as marker of cardiac 
pathology and stress (Maisel, 2001). Finally T-type Ca2+ channels are abundantly expressed in 
fetal myocardium, normally absent in adult hearts and its expression is restricted to conduction 
system. In adulthood, cardiac expression of T-type Ca2+ channels, which can be induced in 
hypertrophic conditions and failing hearts, is a hallmark of arrhythmias and ventricular 
dysfunction (Kuwahara et al., 2012). ANP and BNP increase in hearts with depressed ventricular 
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functionality independently from hypertrophy; whilst αSA increases in hypertrophic mouse 
models during progression towards heart failure (Dorn et al., 2003).  
Hypertrophic gene expression and fetal genes reactivation are regulated by transcription factors 
such as NFAT, MEF2, GATA4. Fetal gene activation is regulated by epigenetic changes and 
modifications, which potentially offer new therapeutic targets (Kuwahara et al., 2012; Dirkx et 
al., 2013). 
 
1.4.4 Animal models  
 
Animal models are essential to study the pathogenesis of a disease and to develop new 
therapeutic strategies. For cardiovascular disease studies, animal models for myocardial 
infarction, hypertension, HF, cardiac hypertrophy and fibrosis have been developed. For HF 
research, mammals of several sizes can be used: bovine, sheep, dog, pig, rabbit, rat, guinea pig, 
turkey, cat, and hamster. Animal models for heart failure and cardiac hypertrophy have 
limitations or advantages depending on the aim of the study they are used for; as for all animal 
models, the similarity with the human pathology needs to be taken in consideration (Hasenfuss, 
1998; Rai et al., 2016). In the past, rats were extensively used for HF and cardiac hypertrophy 
studies. For studies on the transition from hypertrophy to HF, the three main rat models are: 
spontaneous or Dahl salt-sensitive hypertension models that develop reduced myocardial 
functionality as a consequence of hypertension, and, finally, the binding of suprarenal aorta 
model (Hasenfuss, 1998). Hypertension models have been developed also in mice, using chronic 
intravenous infusion of renin and AngII (Carnevale et al., 2014). 
Thanks to the development of microsurgical procedures, in 1991 a pressure-overload (PO) 
induced HF mouse model was created, the Transverse Aortic Constriction (TAC) mouse model. 
This is currently used as gold-standard model for HF studies (Rockman et al., 1991). TAC-
operated mice have a high surgical survival rate, develop left ventricle hypertrophy, reduced 
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cardiac functionality, increased fibrosis, and increased expression of fetal gene (i.e. ANF and 
Mhy7). Besides TAC, other PO mouse models are used and they include ascending aortic 
binding, abdominal aortic constriction, and TAC with distal left anterior coronary ligation 
(Rockman et al., 1991; Rai et al., 2016). PO induces early morphological changes in 
cardiomyocytes as soon as 2 days after TAC, with increased cardiac hypertrophy (measured as 
relative wall thickness as well as heart weight to body weight) and reduced endothelial cell 
population together with increase acute inflammatory response. After 1 week, TAC mice have 
increased collagen deposition and myocyte width; after 4 weeks, TAC mice present a marked 
heart dysfunction (Souders et al., 2012). Finally, genetic models have been developed to study 
the function of single genes in specific pathophysiological process such as cardiac fibrosis or 
hypertrophy independently from cardiac dysfunction (Rai et al., 2016). 
 
1.5 Fibroblasts: differentiation and functions  
 
The heart of vertebrates is constituted by cellular and acellular components. The cellular 
compartment is represented by cardiac myocytes and non-myocytes surrounded by the acellular 
compartment that is the extracellular matrix (ECM), which provides scaffold for individual 
myocytes and for the whole heart. (Gourdie	  et al., 2016; Baudino et al., 2006).   
The acellular component, ECM, is composed by interstitial collagen, proteoglycans, 
glycoproteins that form a 3D network that interconnects with the cellular components. In 
addition to providing scaffold for both myocytes and non-myocytes, ECM also has a role in 
distributing mechanical forces throughout the whole heart, as well as transmitting mechanical 
signals to individual cells via cell surface receptors (mechanotransduction). Finally in ECM 
growth factors, cytokines and proteases can also be found.  The ECM also participates in 
movement of the extracellular environment (Baudino	  et al., 2006; Gourdie	  et al., 2016). 
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Non-myocyte cellular components include endothelial cells, mast cells and fibroblasts. Although 
the bulk of myocardial volume is represented by cardiomyocytes, cardiac fibroblasts, in terms of 
numbers, are the most frequent cell type and have a key role in cardiac tissue. Indeed in a healthy 
heart 60-70% of the cells are fibroblasts and only the remaining 30-40% is composed of 
cardiomyocytes (Van Linthout	   et al., 2014). According to more detailed studies on animal 
models, the murine adult heart is composed by 56% cardiomyocytes, 27% fibroblasts, 7% 
endothelial cells and 10% vascular smooth muscle cells (Fujiu and Nagai, 2013). In adult rat 
hearts, 64% are fibroblasts, 30% cardiomyocytes, endothelial cells, and vascular smooth cells 
and only 6% are immune cells (Fujiu and Nagai, 2013).  
Fibroblasts are cells of mesenchymal origin, essential for tissue remodeling. They generate and 
maintain the connective tissues by production of interstitial collagen (Gourdie et al., 2016; 
Baudino et al., 2006).  The name itself “fibroblasts”, which derives from the Latin word fibra 
(fiber or filament) and from the Greek word blastos (germ or sprout), suggests the main function 
of this cellular population. Fibroblasts, besides collagen production, have biochemical, paracrine 
and juxtacrine interactions with cardiomyocytes; and due to their ability to respond to 
mechanical, electrical and chemical stimuli fibroblasts have an active role in preservation of 
cardiac function (Kakkar and Lee, 2010; Gourdie et al., 2016; Fujiu and Nagai, 2013; Kohl et al., 
2005). The interaction between fibroblasts and cardiomyocytes is essential in physiological 
development and remodeling as well as in response to tissue damage and under pathological 
conditions (Van Linthout et al., 2014; Gourdie et al., 2016). In fact, in response to stress, 
quiescent cardiac fibroblasts change phenotype and differentiate into myofibroblasts (myoFb). 
MyoFb are spindle-shaped fibroblast-smooth cell hybrid with dendritic-like processes, 
contractile properties and ability to produce collagen (Davis and Molkentin, 2014; Gourdie et al., 
2016). MyoFb differentiation is a two-step process. Initially fibroblasts develop into proto-
myofibroblasts, which express cytoplasmic actin fibers and small adhesion molecules. Thanks to 
adhesion molecules, proto-myofibroblasts can migrate to the wounded area where they start to 
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secrete collagen. Cytokines and mechanical stress induce proto-myofibroblasts to acquire a 
mature phenotype. Proto-myofibroblasts are highly sensitive to proinflammatory cytokines, such 
as interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and 
transforming growth factor beta (TGFβ); as well as vasoactive peptides such as AngII, ANP and 
BNP (Porter and Turner, 2009). The newly acquired phenotype can be distinguished by 
expression of αSMA and super-adhesion cadherin-2 and 11 proteins. At this point myoFb 
capability to migrate towards damaged tissue area is enhanced thank to their fully active 
contractile activity (Davis and Molkentin, 2014). 
 
1.5.2 Collagen synthesis  
 
Acute injury and tissue damage are usually followed by a scaring process called fibrosis, during 
which the deposition rate of new collagen fibers and of non-collagenous ECM is higher then the 
degradation (Daskalopoulos et al., 2016; Van Linthout et al., 2014). In fact, cardiac fibrosis is 
part of the structural remodeling that the myocardium undergoes, during several pathologies such 
as myocardial infarction, pathological cardiac hypertrophy and heart failure. Cardiac fibrosis has 
a variety of consequences. Above all, it leads to myocardium stiffness, responsible for reduced 
organ functionality (Kong et al., 2014; Gourdie	  et al., 2016; Van Linthout et al., 2014). Fibrosis 
formation in myocardium has two main patterns: reparative fibrosis and reactive fibrosis. 
Reparative fibrosis is the formation of a focal fibrotic scar and it is present mostly in myocardial 
infarction (MI). On the other hand, end-stage HF reactive fibrosis is a diffuse fibrosis formation 
in interstitial and perivascular spaces (Heymans et al., 2015). Irrespective of its etiology, cardiac 
fibrosis is characterized by increased deposition of both type I and type III interstitial fibrillar 
collagen (Van Linthout et al., 2014). The amount of collagen but also the degree of cross-linking 
of the fibers directly correlates to myocardial stiffness (Badenhorst et al., 2003; Daskalopoulos et 
al., 2016). 
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Collagen is a protein with a 90-120 day half-life, and can divided into 18 types. The most 
abundant collagen type in human connective tissues is type I; 85% of cardiac ECM is composed 
of type I collagen and 11% of type III collagen with a small presence of type IV and VI. The 
main difference between type I and type III is the level the crosslinking between the fibers: type I 
forms thicker fibers with more crosslinking. In cardiac fibrosis type I/ type III ratio increases (de 
Jong et al., 2011); in myocardial infarction animal models, type I has a more sustained 
upregulation compared to type III collagen. Even if it is not the most abundant collagen form, 
non-fibrillar type VI collagen can activate fibroblasts as well as induce in-vitro 
transdifferentiation from fibroblasts to myoFb. Type VI collagen effects in vivo are still 
controversial as it has also been shown to disrupt the fibrotic process and improve cardiac 
function after myocardial infarction (Naugle et al., 2006; Kong	  et al., 2014). 
 
1.5.3 Regulation of cardiac fibroblast activation and fibrosis 
 
Exposure to stress induces fibroblast proliferation and differentiation; in fact hypoxia, 
mechanical stress (hypertension) and inflammation can trigger fibrosis. AngII, TGFβ, and other 
molecules can stimulate fibroblast differentiation and consequently lead to cardiac fibrosis.  
TGF-β is a class of cytokines that includes 3 isoforms. TGFβ is produced by platelets, immune 
cells such as macrophages, injured epithelial cells and fibroblasts in response to inflammation 
(Tomasek et al., 2002). Among the several activities in which they are involved, we can list 
regulation of inflammatory response, ECM deposition, cell proliferation and differentiation 
(Dobaczewski et al., 2011).  
TGF-β in cardiac injuries has a plethora of effects. First of all, together with collagen VI 
deposition, it can control fibroblast phenotype, inducing αSMA expression (Kong et al., 2014). 
Even though αSMA expression in myoFb can be directly increased also by mechanical stress, 
TGFβ presence is essential to fully trigger myoFb differentiation (Kong	   et al., 2014). TGFβ 
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induces focal adhesions and stress fibers, important for the transition from pro-myoFb to mature 
myoFb (Tomasek et al., 2002). 
TGFβ increases ECM synthesis, inhibits Matrix Metalloproteinase (MMP) activity and induces 
tissue inhibitors of metalloproteinases (TIMPs) (Dobaczewski et al., 2011). MMPs are zinc-
dependent proteases synthetized mainly by fibroblasts and existing in more than 20 types. MMP-
1, MMP-8 and MMP-13, also known as collagenase, cleave type I and III collagen into 2 
fragments that will denature at physiological conditions and be digested by MMP-2 and MMP-9, 
known as gelatinases. MMP-9 can also induce profibrotic pathways and increase collagen 
accumulation in ECM. MMP activity is regulated by a class of enzymes known as tissue 
inhibitors of metalloproteinases (TIMPs). There are 4 identified types of TIMP family enzymes. 
TIMPs bind the catalytic site of MMPs, abolishing their cleavage activity. Furthermore TIMPs 
can also induce fibroblast differentiation into myoFb, induce collagen synthesis and cell 
proliferation. The interaction between TIMPs and MMPs is crucial in all collagen-related disease 
but also in tumor metastasis process (de Jong	  et al., 2011). TGFβ is secreted as inert form and 
needs to be activated after secretion; MMP-2 and MMP-9 can cleave the inert form of TGFβ 
(Dobaczewski	  et al., 2011; Berk et al., 2007).  
Therapeutic attempts in order to regulate cardiac fibrosis formation have been conducted in 
myocardial infarction animal models.  Considering the importance of TGFβ signaling has been 
developed an orally active TGFβ Type 1 receptor (ALK5) inhibitor. ALK5 inhibitor was able to 
reduce collagen accumulation and cardiac hypertrophy, and improved systolic function (Tan et 
al., 2010).  
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Part 2 - The immune system 
 
The immune system is a sophisticated and complex system that includes several cell populations 
and molecular effectors; it has evolved in order to defend the organism from pathogen infections. 
Vertebrates have two branches of immune defense: innate immunity, that activates a rapid 
defense reaction immediately after the appearance of a pathogen, and adaptive immunity that 
generates a highly specific response at a subsequent timepoint, which can efficiently eliminate 
pathogens and provides long-lasting protection. Innate immunity is composed of macrophages, 
neutrophils, dendritic cells (DC), mast cells, natural killer cells (NK), basophils and eosinophils.  
Besides cellular mediators, innate immunity acts also via activation of the complement cascade 
and production of inflammatory cytokines and chemokines. One of the major functions of innate 
immunity is to activate adaptive immunity. The latter is composed of two classes of 
lymphocytes: B lymphocytes (B cells) and T lymphocytes (T cells). B cells are generated in the 
bone marrow and are responsible for the secretion of antibodies, which are small proteins of the 
immunoglobulin family. On the other hand, T cells, which originate in the thymus, are divided 
into different classes that can either enhance the activity of other immune cells or directly 
eliminate infected cells (Alberts et al., 2007). 
 
2.1 T lymphocytes  
 
T cells are divided in two categories: cytotoxic T cells and T helper cells. Cytotoxic T cells are 
mainly responsible for the killing of infected cells while T helper cells support the activity of 
other cells of the immune system through cytokine production. T helper cells sustain B cell 
activation and antibody production; help DC to activate T cells and macrophages to eliminate 
pathogens, and recruit and activate cytotoxic T cells. Cytotoxic and T helper cells can be 
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distinguished by the expression of surface markers CD8 in cytotoxic T cells (CTL) and CD4 in T 
helper cells (Th) (Janeway	  et al., 2001). 
 
2.1.1 T helper cells 
 
CD4 Th cells are divided into several subsets: Th1, Th2, Th17, Th22, Th9 and T follicular help 
(Thf). The different Th classes are distinguished by their cytokine production profile, different 
homing chemokine receptors and specific transcription factors. The first identified and cloned 
classes of Th are Th1 and Th2, classified on the basis of different cytokine production 
(Mosmann et al., 1986). Th1 cells mainly produce INFγ, IL-2 and TNFα whilst Th2 produce IL-
4, IL-5, IL-9 and IL-13. Th1 activate macrophages and respond against intracellular pathogens 
(Zhu and Paul, 2010). Th2 are involved in allergic reaction and asthma, inducing IgE production, 
elimination of extracellular pathogens such as helminths, alternative activation of macrophages 
and can also affect epithelial cells (Zhu, 2015). The later discovered Th17, which are generated 
in response to IL-6 and IL-23, produce IL-17a, IL-17f, IL-21 and IL-22 (Zhu and Paul, 2010).  
Th17 are involved in many autoimmune diseases and in the defense against extracellular 
pathogens. Other subsets are Th22 that activate response against Gram-negative bacteria, Th9 
that are involved in asthma, and Tfh that have essential functions in germinal centers (Cosmi	  et 
al., 2014). The classes of T helper cells are distinguished by the expression of master 
transcription factors. Each class is involved in different aspects of the immune response, 
producing different cytokines and utilizing different chemokines and chemokines receptors to 
migrate to the site of infection (Janeway et al., 2001). Indeed T helper cells differentiate from 
naïve CD4+ T cells in response to cytokines present in the microenvironment, which differ 
according to the nature of the pathogen. The naïve T cells upregulate specific transcription 
factors, which are crucial for the differentiation of each class (Zhu and Paul, 2010). T-box 
protein (T-bet or TBX21) is the transcription factor that mediates Th1 differentiation (Szabo et 
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al., 2000). T-bet binds to Infg promoter and induces IFNγ production; T-bet expression can 
redirect Th2 polarized cells into Th1 and absence of this transcription factor leads to failure of 
Th1 differentiation (Szabo et al., 2000; Oh and Hwang, 2014). IFNγ binding to its receptor 
enhances Tbet expression and activates STAT1 (Oh and Hwang, 2014).  Th2 develop in 
response to IL-4 and IL-4R signaling activating GATA-3 and STAT6. GATA-3 is the lineage 
transcription factor for Th2 and regulates the expression of type-2 cytokines together with 
STAT6, which is necessary for chromatin remodeling of the IL-4/IL-13 locus (Szabo	   et al., 
2000; Zhang	  et al., 1997).   
Besides cytokine production, lymphocyte trafficking is another way to control immune 
responses. Recruitment of T cells in different tissues interferes with their differentiation and 
therefore with their functions. Upon differentiation into polarized Th subsets, the migration of 
the T cells is mediated by differential expression of chemokine receptors, which respond to 
cognate chemokines. Th1 cells express CCR2, CCR5, CXCR3 and CXCR5 thus respond to 
chemotactic gradients created by CCL2, CCL5, CXCL9, CXCL10 and CXCL11. Th2 express 
CCR3, CCR4 and CCR8 (Sallusto et al., 1998). 
 
2.1.2 T cell Activation and Costimulation. Role of CD80/86 and CD28. 
 
T cells need to be fully activated via two signals in order to function. The first is the activation of 
the T cell receptor (TCR) by recognition of an antigen and the second is the costimulation that 
occurs independently from the antigen recognition (Frauwirth and Thompson, 2002; Alberts et 
al., 2007). The antigen recognition by a TCR is mediated by antigen presentation from a host 
cell, acting as an Antigen Presenting Cell (APC), which could be dendritic cells, B cells, or 
macrophages. Firstly the innate immune system is activated via pattern recognition receptors that 
can detect microbial and viral products or microorganism-mediated metabolic changes. 
Activated APCs increase the amount of major histocompatibility complex (MHC) molecules on 
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their cell surface. MHC complexes are glycoproteins and are divided into two classes: MHC 
class I are expressed on the majority of the cells, except for erythrocytes, whilst MHC Class II 
(in mice) is expressed only on APC. MHC Class I molecules present pathogen-derived antigens 
on the surface of infected cells. MHC Class II molecules present antigens from pathogens that 
have been endocytosed by APC. For the pathogen proteins to be presented to T cells, the proteins 
need to be processed and a small peptidic sequence (the antigen) are bonded to the MHC. APC 
migrate to peripheral lymphoid organs to activate naïve T cells (Janeway	  et al., 2001; Alberts et 
al., 2007; Josefowicz	  et al., 2012). Yet, in order to be fully activated, T cells need to receive a 
second costimulatory signal. If TCR receives a very strong signal, it is possible to activate T 
cells in absence of costimulation. Costimulation is nonetheless critical for cell proliferation, 
differentiation and cytokine production; in absence of costimulation T cells undergo antigen-
specific unresponsiveness (anergy) and/or apoptosis (Sharpe, 2009). Costimulation occurs via 
the binding of costimulatory molecules during interactions between T cells and APC. 
Costimulatory proteins on the surface of the APC can activate either negative or positive signals 
in matching receptors on the T cells. The balance between negative and positive costimulatory 
pathways (which may not necessarily appear concurrently) is crucial both to maximize immune 
responses and maintain immune tolerance.  The most extensively-studied pathway for positive 
costimulation is via B7-1(CD80)/B7-2(CD86)-CD28. Murine T cells constitutively express 
CD28, whilst CD86 is constitutively expressed at low levels on the majority of APC and is 
quickly upregulated after APC activation; CD80 requires APC activation to be expressed. The 
different timing for the expression of these two receptors suggests that CD86 may be more 
important (Sharpe and Freeman, 2002). Cd28-gene deficient mice have reduced T cell activation 
even though not completely abrogated (Walker and Sansom, 2011). After TCR and CD28 have 
been engaged, T cells form stable immunological synapses (IS), necessary for the complete 
activation of the T cell (Sharpe, 2009). The T cell itself, after activation, exerts a costimulatory 
effect on the DC, reinforcing the ability of the DC to present the antigen, inducing production of 
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pro-inflammatory cytokines and expression of costimulatory molecules. Activated Th can 
proceed to expand, to induce class-switched antibody production by B cells, and induce 
macrophages to kill pathogens (Janeway	   et al., 2001). CD28 intracellular signals amplify the 
activation of NFkB and NFAT that is initiated by TCR signaling (Rudd	  et al., 2009). Besides 
CD28, other costimulatory molecules, such as ICOS can induce T cell differentiation and 
activation. ICOS ligand is expressed in many cell types, such as B cells, monocytes and DC 
under IFNγ stimulation (Sharpe and Freeman, 2002).  
 
2.1.3 Pathways inhibiting costimulation  
  
Immune regulation is essential for the maintenance of peripheral tolerance and to limit no-longer 
required immune responses. There exists a class of CD4+ T cells, termed regulatory cells (Treg) 
that will be extensively presented in the next section. Besides the functions of Treg, immune 
responses are regulated via immune checkpoints and co-inhibitory receptors that can induce T 
cell unresponsiveness and block immune responses (Murakami and Riella, 2014). Within the B7-
CD28 superfamily there are the two principal co-inhibitory receptors: programmed death-1 (PD-
1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA4) (Sharpe and Freeman, 2002).  
 
2.1.3.1 PD-1  
 
PD-1, also known as CD279, was first identified on the cell surface of T cells during 
programmed cell death. PD-1 is an inhibitory receptor expressed on exhausted T cells, B cells 
and myeloid cells; it shares structural similarities with CD28 and its ligands are PD-L1 and PD-
L2. PD-L1 is constitutively expressed on macrophages, resting T and B cells; its presence can 
also be detected on non-hematopoietic cells such as endothelial cells in the myocardium and in 
the placenta. Most importantly, many different tumor types express it. PD-L2 expression can be 
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induced on professional APC. PD-1 signaling inhibits Th and cytotoxic T cell function and 
induces peripheral Treg maturation (Sharpe and Freeman, 2002; Murakami and Riella, 2014). 
PD-1 negative function is exerted in the periphery by negatively regulating previously activated 
T cells, as well as blocking T cell proliferation and production of IL-2 and IFNγ. Interestingly, 
the binding of the two ligands seems to have opposite effects, as PD-L2 has been shown to 




CTLA4 binds CD80/CD86 in a competitive way with CD28 and with higher affinity 
(Buchbinder and Desai, 2016); the importance of this molecule for the maintenance of immune 
homeostasis is supported by the fact that Ctla4-/- mice die within 3 weeks of age because of 
massive organ infiltration and damage in consequence of lymphoproliferation (Waterhouse	  et al., 
1995). CTLA4 is localized in intracellular compartments such as endosomes, Golgi network and 
lysosomes and is continuously internalized; thus the surface expression is very low. CTLA4 
expression on the cell surface is induced by TCR ligation to MHC-peptide complexes, with the 
exception of Treg, which express it constitutively (Walker and Sansom, 2011). Several 
mechanisms of action have been proposed for CTLA4-mediated inhibitory effects on T cell 
activation. The described molecular mechanisms of action of CTLA4 include competitively 
binding to CD80/CD86 (with higher affinity than CD28), and activating indoleamine-2,3-
dioxygenase (IDO) in DC, which via consumption of tryptophan and production of kynurenine 
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2.2 Regulatory T cells 
 
In order to maintain immune homeostasis and control unwanted inflammatory responses, 
organisms have developed several regulatory mechanisms. The key mediator of these 
mechanisms in mammals (Andersen	   et al., 2012) is a class of immunosuppressive cells: 
regulatory T cells (Treg) (Vignali	  et al., 2008). Treg are characterized by the expression of CD4 
and CD25 as surface markers and their differentiation is driven by and dependent on the 
expression of forkhead box P3 (FOXP3) transcription factor. Treg represent 10% of peripheral 
CD4 T cells (Wing and Sakaguchi, 2010; Hori et al., 2003). Gershon first identified an 
immunoregulatory T cell population in 1970, and defined them suppressor T cells (Gershon and 
Kondo, 1970). Suppressor T cells were at that time identified as CD8a+ cells and thus could not 
be distinguished from CD8 cytotoxic T cells; there were also several ambiguities in identifying 
genetic markers for suppressor T cells (Aluvihare	  et al., 2005).  In 1995 Sakaguchi identified a 
CD4+CD25+ suppressive population of T cells; this population was able to block autoimmune 
responses. In fact depletion of CD4+ CD25+ or transfer of CD4+ CD25- T cells in nude (T cell-
less) mice was sufficient to induce organ-specific and systemic autoimmune responses; the 
reconstitution of the CD25+ population was sufficient to block this effect (Sakaguchi	   et al., 
1995). In 2001 the genetic mutation that causes the IPEX (immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked) syndrome was identified (Bennett	  et al., 2001). The 
syndrome is caused by a mutation in the Foxp3 gene. The orthologous gene of Foxp3 was first 
identified in scurfy mice. Scurfy mice have a mutated form of Foxp3 that induces the 
development of an IPEX-like syndrome. IPEX is characterized by severe autoimmune syndrome 
in endocrine organs, manifested as diabetes and thyroiditis, hyper-IgE syndrome, exfoliative 
dermatitis and systemic inflammation (Bennett	   et al., 2001). Foxp3 is a transcription factor 
belonging to the forkhead box winged helix (Fox) transcription factors: Foxp1, Foxp2 and Foxp4. 
The Forkhead (FKH) domain is responsible for the nuclear localization of the protein, the DNA-
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binding and for the interaction with NFAT (Andersen	  et al., 2012). Foxp3 expression in CD4+ 
CD25- cells induces phenotypic and functional conversion into of effector T cells into Treg. 
Foxp3 presence is essential for the development and maintenance of Treg (Hori	  et al., 2003). The 
chronic ablation of Treg in diphtheria toxin receptor (Foxp3DTR) knock-in mice causes death 
within a few weeks and induces a scurfy-like phenotype. The effects caused by depletion of 
Foxp3+ cells demonstrated that expression of Foxp3 in Treg is crucial for the maintenance and 
function of Treg, and that Treg are essential for immune homeostasis (Lahl	   et al., 2007). 
Although Foxp3 is a specific marker for murine Treg, in humans its expression is not as rigidly 
specific for Treg cells, as a small percentage of activated T cells can also express it. Indeed 
human Treg are usually identified using markers as CD4+CD25+CD127low in order to circumvent 
the problem of non-exclusive Foxp3 expression (Vignali	  et al., 2008). 
 
2.2.1 Treg development, nTreg, pTreg and iTreg 
 
Foxp3+ Treg principally develop in the thymus and are referred as tTreg (thymus Treg) or nTreg 
(natural Treg). Yet Treg can also develop in the periphery, from Foxp3- conventional Th cells; 
these Treg have been termed pTreg (peripheral Treg); moreover since in vitro Treg can be 
generated by Il-2 and TGGF-b from naïve T cells, these have been termed iTreg (inducible Treg) 
(Shevach and Thornton, 2014). nTreg develop in the thymus, possibly from CD4+ T cells that 
recognize self-antigens with higher avidity. Usually thymocytes that bind with high avidity self-
antigens undergo negative selection and cell death in order to avoid the generation of self-
reactive T cells (Gratz et al., 2013). CD4+ that interact with self-antigens with intermediate 
strength may be those cells that will express Foxp3 and become nTerg. The TCR repertoire of 
nTreg is distinct from pTreg thus suggesting that the differentiation of pTreg occurs in a different 
way. It has been suggested that pTreg differentiation is driven by recognition of non-self 
antigens with high affinity together with suboptimal costimulation. Under homeostatic non-
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inflammatory conditions, chronic exposure to non-self antigens, such as those from commensal 
bacteria, in the presence of high amounts of TGFβ, support the generation of pTreg (Josefowicz 
et al., 2012). It has also been reported that PD-1 can induce pTreg amplification: its expression 
on DC can induce naïve T cell differentiation into pTreg. PD-1 is then expressed on pTreg and 
promotes APC anergy (Murakami and Riella, 2014). 
 
2.2.2 Mechanisms of action of Treg 
 
The understanding of Treg suppressive mechanisms is crucial in order to take advantage of their 
capability to control immune responses. Mechanisms of suppression of Treg can be classified 
into 4 categories, even though studies on this question are still ongoing:  
1- suppression by soluble factors 
2- suppression by cytolysis 
3- suppression by interference with cell metabolism 
4- suppression by cell-to-cell contact with DC (Vignali 2008). 
The suppression by soluble factors includes two different mechanisms. The high expression of 
CD25, which is the a-chain of IL-2R, on Treg cell surface is responsible for a high IL-2 
consumption by Treg, therefore inducing a cytokine-deprivation-induced apoptosis in T effector 
cells (activated Th or CTL) (Pandiyan et al., 2007). Further, secretion of inhibitory cytokines, 
including IL-10, TGF-b and IL-35, mediates Treg suppressive function (Wing and Sakaguchi, 
2010). IL-10 production by Treg is essential in allergic responses and asthma to control this type 
of immune response, as well as in inflammatory bowl diseases (Vignali et al., 2008). IL-10 
deletion in Treg results in increased inflammatory responses in colon, lung and skin. This 
suggests that IL-10 produced by Treg is essential to block immunological hyperreactivity 
(Rubtsov et al., 2008).  
The cytolysis of target cells by Treg is mediated in a granzyme-dependent manner. Human Treg 
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can express granzyme A and kill in a perforin-dependent manner activated T effector cells. 
Murine Treg, on the other hand, express granzyme B and thus can induce cell death in a perforin-
independent way to mediate their suppressive function. Treg lacking granzyme B have reduced 
suppression activity in vitro. Treg expression of granzyme B in vivo has been demonstrated only 
in the tumor microenvironment, where Treg mediate NK cell and CD8 cell death (Vignali et al., 
2008; Shevach, 2009).  
Treg can interfere with cell metabolism via CD39 and CD73. CD39 and CD73 are ectoenzymes 
that induce pericellular secretion of cAMP, a potent inhibitor of T cell growth. The binding of 
cAMP to A2A receptor, besides blocking T cell proliferation, increases production of TGFb, 
modulates DC maturation and decreases IL-6 release (Josefowicz et al., 2012; Vignali et al., 
2008; Bopp et al., 2007).  
Finally Treg can modulate DC maturation via cell-mediated suppression of the expression of 
surface molecules. Treg interactions with DCs inhibit the formation of stable immunological 
synapses (Tadokoro et al., 2006; Sarris et al., 2008). Treg downmodulate DC costimulatory 
molecules and their ability to present antigen to Th and CTL, thus blocking full activation of the 
T cells (Shevach et al., 2011). Treg, both human and murine, are the only lymphocytes that 
highly express CTLA4 constitutively (Wing et al., 2010; Vignali et al., 2008). Blockade of 
CTLA4 with monoclonal antibody inhibits Treg suppressive function and induces organ-specific 
autoimmunity (Takahashi et al., 2000). The key role of CTLA4 in Treg is furthermore supported 
by the fact that the absence of this molecule on Treg results in systemic lymphoproliferation, 
hyper-IgE production and autoimmune reactions (Wing et al., 2008). Another Treg surface 
molecule that suppresses DC maturation is LAG3 (CD223) that binds MHC Class II with high 
affinity. The binding of LAG3 to MHC Class II induces activation of an ITIM-mediated 
inhibitory pathway and leads to block of DC maturation (Vignali et al., 2008; Shevach, 2009).  
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2.3 CTLA4-Ig Abatacept 
 
CTLA4-Ig, or abatacept (Orencia; Bristol-Myers), is a human fusion protein composed by the 
extracellular domain of human CTLA4 fused to Fc portion of IgG1 human immunoglobulin 
approved in 2005 by US FDA for the treatment of Rheumatoid Arthritis (RA) patients; abatacept 
binds CD80/CD86, impeding CD28-mediated costimulation T cell (Moreland et al., 2006). 
Abatacept administration to RA efficiently reduces the symptoms, enhances Treg activity and 
suppresses T cell hyperactivation (Kremer et al., 2003). Besides its clinically approved 
application, CTLA4-Ig has been reported to inhibit specific T cell activation in other 
autoimmune diseases (systemic lupus erythematous and experimental autoimmune 
encephalomyelitis), Graft-versus-host-disease and in organ transplantation (Wu et al., 2012).  
Abatacept is overall well tolerated with few allergic reactions and few adverse side effects 
(Moreland et al., 2006). Since Abatacept has been used in clinic for several years many clinical 
trials have been conducted. Data collected form 8 phase IV clinical trials reported that treatment 
with Abatacept in RA patients did not increase the risk of serious infections compared to other 
biological modifiers generally used for RA treatment; however Abatacept cannot be used in 
combination with other immunomodulatory drugs in order to avoid the increase risk of 
infections. Frequency of malignancies in patients treated with Abatacept was comparable to the 
frequency of RA patients that under other therapies; especially considering that some 
malignancies are associated with RA itself (Weinblatt et al., 2013; Askling et al., 2009). Finally 
the risk of autoimmune side effects what restricted to rare manifestation of psoriasis (Weinblatt 
et al., 2013).  
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2.4 B lymphocytes 
 
Humoral immunity, in contrast to cell-mediated immunity, is the part of the immune response 
mediated by molecules secreted in body fluids. B cells represent the principal cell population of 
the humoral response due to their ability to produce antibodies (Janeway et al., 2001). In most 
mammals there exist five classes or isotypes of antibodies: IgA, IgD, IgE, IgG and IgM. The 
fundamental structure of an antibody monomer includes two identical light chains (L) and two 
identical heavy chains (H), two identical antigen-binding sites formed by the N-terminal region 
of the heavy and the light chain. The heavy chain constant region (CH) determines the antibody 
class as each class has its own heavy chain (α, δ, ε, γ and µ). During B cell development light 
and heavy chains undergo molecular rearrangement of the variable (V), diversity (D) and joining 
(J) gene segments. This process is called, respectively for light and heavy chain, V-J and V-D-J 
recombination (Manis et al., 2002; Stavnezera and Amemiya, 2004; Vazquez et al., 2015). This 
recombination process generates a unique B cell receptor (BCR), which is a membrane-bound 
antibody, and determinates the antigen that will be recognized by each B cell clone. BCR 
expression is essential for the maturation process of B cell precursors and for their survival; 
mature B cells can co-express IgM and IgD when migrate from the bone marrow to the 
secondary lymphoid organs where start the antigen-dependent phase of maturation. The 
encounter of an antigen activates naïve B cells that proliferate and differentiate (Alberts	  et al., 
2007; Cerutti et al., 2013). Th-cell mediated costimulation of B cells then determines the 
secretion of the soluble form of IgM and class switch, with secretion of either IgG, IgE or IgA 
soluble forms (Stavnezera and Amemiya, 2004).  
In recent years other functions have been attributed to B cells, such as antigen presentation and 
cytokine production (Mauri 2012). B cells also contribute to autoimmune diseases via production 
of auto-antibodies (autoAb) (Korganow et al., 1999).  
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Immunosuppressive B cells expressing CD1d and IL-10 were identified in chronic inflammatory 
bowl disease mouse model, where they contribute to the suppression of inflammatory response 
(Mizoguchi et al., 2002). Indeed IL-10 production confers regulatory functions to B cells; hence 
this population is termed regulatory B cell (Breg). It has been shown that Breg can suppress 
inflammatory responses in different autoimmune models such collagen-induced arthritis (CIA), 
EAE, multiple sclerosis mouse models and colitis (Mauri and Bosma, 2012). In a healthy mouse 
Breg are 1-5% of the splenic or lymph nodal B cells. Breg phenotypically can be distinguished 
based on cell surface markers CD19, CD1dhigh and CD5. Breg cells can expand in response to 
signals through Toll-like receptors (TLR), BCR and CD40 stimulation in vitro (Floudas et al., 
2016). IL-10 produced by Breg can negatively influence DC antigen presentation and inhibits 
IFNγ and IL-17 production, thus reducing Th1 and Th17 differentiation. Importantly, it has been 
shown in several mouse models that Breg via IL-10 production can positively influence 
generation and maintenance of Treg via CD80/CD86 interaction. (Mauri and Bosma, 2012; 
Floudas et al., 2016; Mann et al., 2007; Carter et al., 2011).  
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Part 3 - Inflammation in cardiac hypertrophy and HF 
 
Cardiac remodeling, hypertrophy and fibrosis in HF are accompanied by systemic inflammatory 
response and immune cell infiltration and activation (Frieler and Mortensen, 2015; Hofmann and 
Frantz, 2013). The first description of inflammatory mediators in HF patients is from 1990 
(Levine et al., 1990) and since then, the link between inflammatory response and pathology of 
cardiac diseases has become a distinct and growing research field (Mann, 2002). The trigger of 
the inflammatory response in HF is still unknown. Among the possible causes there is the 
mechanical stress that cardiomyocytes undergo during PO, whilst also hypoxia, together with 
gemneration of reactive oxygen species (ROS), is a potent inflammatory inducer (Hofmann and 
Frantz, 2013). In disease progression inflammatory cytokines are involved. The immune 
response in MI has been extensively studied; the early phases of post-MI response are different 
from the chronic alterations that occur in cardiac hypertrophy and HF (Frieler and Mortensen, 
2015). 
Three phases characterize the inflammatory response that occurs in consequence of cardiac 
injury:  
1- production of inflammatory mediators (cytokines and chemokines) 
2- recruitment of immune cells that intervene in tissue remodeling process  
3- anti-inflammatory mediators that stop the inflammatory response (Ghigo et al., 2014).  
 
3.1 Cytokines and chemokines in HF 
 
Studies conducted in recent years have extensively investigated the presence and role of 
cytokines in HF patients and in animal models. Increase of these cytokines in the blood indicates 
an immune activation inside the myocardium, which can be itself a source of the circulating 
cytokines. (Hofmann and Frantz, 2013) The first cytokine detected in patients with HF is TNFα 
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in 1990 by Levin et al; since then IL-6, IL-1b and IL-18 (Hartupee and Mann, 2013) have also 
been identified as being present in significantly high levels in HF patients. CCL2, CCL3 and 
CXCL8 chemokines are also increased in the blood of HF patients (Gullestad et al., 2012). 
TNFα, IL-6 and IL-1b levels in plasma directly correlate with cardiac dysfunction and disease 
severity. They also correlate with increased mortality of HF patients (Hartupee and Mann, 2013; 
Gullestad et al., 2012; Frieler and Mortensen, 2015) TNFα and IL-6 increased expression has 
been detected also in the myocardium in HF patients, together with chemokine receptors CCR2 
and CXCR1 (Gullestad et al., 2012).  In particular IL-6 and TNFα are independent predictors of 




TNFα in the myocardium has negative effects on contractility. The downstream effect of the 
binding to TNFR1 in the heart is a decreased release of calcium from the sarcoplasmic reticulum 
and a decrease of b-adrenergic receptor (Hofmann and Frantz, 2013). TNFα increase has been 
associated with LV dysfunction and cardiomyocytes apoptosis (Anker, 2004). Studies on animal 
models have demonstrated a causative link between TNFα presence and HF progression. 
Systemic injections of TNFα in rats can induce a dilated cardiomyocyte-like phenotype with 
reduced cardiac functionality; this phenotype was reversed using a chimeric fusion protein of 
TNFR2 with the Fc portion of an IgG1 (TNFR:Fc) acting as TNFα antagonist (Bozkurt et al., 
1998). Mice with cardiac-specific overexpression of TNFα develop dilated cardiomyopathy with 
LV hypertrophy, fibrosis, cardiomyocyte apoptosis and reduced EF. Transgenic mice 
overexpressing TNFα also show increased mortality; mice that died spontaneously presented 
extreme heart dilatation and increased lung weight suggesting a congestive HF-like phenotype 
(Kubota	  et al., 1997). Cardiac-specific overexpression of TNFα has been shown to induce IL-1b 
and IL-6 expression in the myocardium (Kubota	   et al., 2000; Wang et al., 2007). Infusion of 
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TNFα in TNFR1 KO mice failed to induce IL-6 expression but IL-1b levels remained 
significantly high in the myocardium, meaning that the increased expression of IL-1b is 
independent of TNFR1 signaling (Wang	   et al., 2007). Cardiomyocytes and fibroblasts can 




IL-1b in patients is detected in blood stream independently from the cause of HF; it has 
been detected in ischemic cardiomyopathy, hypertensive heart disease and idiopathic 
cardiomyopathy. Increase of IL-1b correlates with (increased left ventricle weight/body weight) 
in rat models of LV hypertrophy and is primarily produced by macrophages. (Sasayama	  et al., 
2000) As for TNFα, systemic injection of IL-1b in mice can reduce LV contractility and 
functionality in a reversible way; indeed 5 days after the end of injections, the heart functionality 
was restored (Van Tassell et al., 2014; Van Tassell et al., 2013). IL-1b has a negative effect on 
cardiac contractility, desensitizing the β-adrenergic receptor (β-AR) and inhibiting L-type 
calcium channels. IL-1b can induce nitric oxide (NO) activity, increasing the aforementioned 
effects (Van Tassell et al., 2014). IL-1b has a synergistic effect with TNFα on heart contractility, 




IL-6 is involved in HF pathogenesis; its effect on cardiomyocytes is more complex than 
the cytokines discussed above. In dog cardiomyocytes, IL-6 can be induced by both IL-1b and 
TNFα, while in human IL-6 is produced by cardiomyocytes and fibroblasts. IL-6 activation can 
occur through two different ways. First IL-6 binds to gp80 (IL-6R), activating dimerization of 
the receptors and gp130 signaling; gp130 is ubiquitously expressed but IL-6R expression is only 
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found in specific cell types. IL-6 can also function via sIL6R (soluble IL-6R), in this case IL-6 
binds sIL-6R and this complex can directly activate gp130 (Szabo-Fresnais et al., 2010). Mice 
overexpressing IL-6 and IL-6R show a consequent constitutive activation of gp130, leading to 
myocardial hypertrophy (Hirota et al., 1995). IL-6 signaling in the myocardium induces a 
hypertrophic response. When IL-6 binds sIL-6R, it activates cellular signaling via STAT3, whilst 
IL-6R signaling does not phosphorylate STAT3 and does not activate an hypertrophic cellular 
response. (Szabo-Fresnais	   et al., 2010) IL-6 infusion in rats induces concentric cardiac 
hypertrophy, fibrosis, and myocardial stiffness. IL-6R is expressed on fibroblasts, though the 
induction of collagen synthesis and myoFb maturation needs the presence of IL-6 soluble 
receptor (sIL-6R) (Melendez et al.,  2010). Under certain stress conditions, cardiomyocytes and 
cardiac fibroblasts can produce IL-6. In particular, cardiomyocytes do so in response to IL-1b 
and fibroblasts to AngII. Human cardiomyocytes in culture produce IL-6, Il-1b and IL-11 
(Ancey et al., 2002). Even though many studies indicate that IL-6 has a detrimental effect on 
myocardium in response to stress, AngII-infusion or PO, the absence of IL-6 is not sufficient to 
prevent LV dysfunction in TAC mice. Il6 KO mice that undergo TAC surgery develop similar 
levels of LV fibrosis and dysfunction to WT. Fetal gene expression upregulation and apoptosis 
were also maintained in these mice, suggesting that the cytokine is sufficient but not necessary 
for the progression of pathology (Lai et al., 2012). IL-6 signaling can have different effects on 
tissue according to the duration of expression. Indeed, acute or chronic presence of this cytokine 
seems to result in different outcomes. In the heart, short-term acute IL-6 presence activates 
compensatory mechanisms and has an anti-apoptotic effect in cardiomyocytes; chronic presence 
induces maladaptive cardiac hypertrophy and, as mentioned above for IL-1b and TNFα, reduces 
cardiac contractility acting negatively on βAR responsiveness (Fontes et al., 2015).  IL-6 
signaling through STA3 induces hypertrophic response; mice with cardiac-specific 
overexpression of STAT3 develop cardiac hypertrophy without any stimulus (Kunisada et al., 
1999).  
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3.1.4 CCL2/CCR2 and other chemokines 
 
Chemokines, which are small chemotactic cytokines, are also found to be increased in HF 
patients and animal HF models. Pressure overload in rats, after suprarenal aortic constriction, 
induces a rapid increase of CCL2 and perivascular infiltration of macrophages within 1 day after 
induction of the model. Block of CCL2 with neutralizing antibodies prevents TGFβ expression 
and fibroblast proliferation (Kuwahara	  et al., 2004). CCL2 in rats with hypertension induces left 
ventricle hypertrophy (Sasayama	  et al., 2000). 
Human heart, both during HF and in healthy conditions, expresses high levels of CC- and CXC-
chemokines (Damas et al., 2000). In addition to CCL2, the myocardium of TAC mice 7 days 
after PO displays an induction of CXCL2 and CXCL10. These chemokines are thought to 
mediate the recruitment of inflammatory cells that contribute to the fibrosis formation and it 




Finally in the immune system, along with pro-inflammatory soluble mediators, anti-
inflammatory mediators also exist; the most potent is IL-10. IL-10 can reduce production of 
TNFα, IL-1b and IL-6; it can also limit production of ROS and macrophage-derived nitric oxide 
(Anker, 2004). IL-10 administration, in TAC mice and in mice with ISO-induced cardiac 
hypertrophy, diminishes mortality and prevents hypertrophy. IL-10 blocks apoptosis by acting on 
caspase-3 activation and NFkB. Il10 KO mice showed a worse outcome in ISO-induced cardiac 
hypertrophy (Verma	  et al., 2012). IL-10 deficiency has similar effects on AngII-injected mice. 
Il10 KO mice infused with AngII develop ventricular dilation and ventricular dysfunction, were 
characterized by a higher increase of proinflammatory cytokines TNFα and IL-6 but also of 
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BNP, which is part of the fetal reactivation program characteristic of HF, compared to WT 
(Kwon	  et al., 2016). 
 
3.1.6 Summary of the role of cytokines in HF 
 
These inflammatory mediators have an active biological role in the pathogenesis of HF; this is 
demonstrated by the fact that many of these cytokines are sufficient to induce HF or HF-like 
phenotype in animal models (Mann, 2015). According to the “cytokine hypothesis” for HF 
progression, HF begins with the pro-inflammatory cytokines cascade within the myocardium, 
which spreads to the circulation, exerting deleterious effects (Seta et al.,1996).  
 
3.2 Cellular mediators  
 
During cardiac remodeling and in response to the release of cytokines, chemokines and other 
mediators, immune cells are recruited, affecting cardiac function (Frieler and Mortensen, 2015). 
 
3.2.1 Monocytes and macrophages 
 
Cardiac macrophages are a heterogeneous population present in health and disease (Frieler and 
Mortensen, 2015). Macrophage depletion in hypertensive rats shows that macrophages are 
necessary for cardiac repair. Depletion of macrophages via liposomal clodronate administration 
in hypertensive Ren-2 rats, which develop hypertension and left ventricle hypertrophy in 
consequence of overproduction of AngII, accelerate the progression of the disease. Rats depleted 
of macrophages have a higher loss of ventricular function accompanied by greater loss of 
cardiomyocytes. In this study, the authors focus on the augmented infiltration of CD4 
hypothesizing that are Th1 or Th17 cells and suggesting that the production pro-inflammatory 
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cytokines by these subsets might be responsible for the deleterious effects on rats. As in the 
absence of macrophages they did not detect collagen deposition, they suggest that the increased 
severity of heart dysfunction in macrophage-depleted rats could be due to missing collagen-
deposition functions mediated by macrophages, affecting the structural integrity of the heart 
(Zandbergen et al., 2009). However they did not consider that cardiac macrophage subsets have 
different phenotypes and functional roles, whilst the methods used in the study depleted all the 
macrophages and peripheral monocytes, irrespective of their cardio-protective or cardio-toxic 
function (Frieler and Mortensen, 2015). The majority of resident macrophages at the steady state 
do not originate from circulating monocytes. Macrophage repopulation in some tissues, such as 
lung, liver, bone marrow and spleen, occurs independently of circulating monocyte recruitment, 
via in situ proliferation. The tissue-resident macrophages are self-renewed and originate from the 
yolk sac (Hashimoto et al., 2013). Kidney, pancreatic, lung and splenic macrophages seem to 
originate from embryonic monocyte-derived macrophages whilst liver, brain and heart contain 
yolk sac-derived macrophages that persist in adulthood. At the steady state, in adult hearts there 
are two macrophage populations. The first is an embryonic lineage from monocytes and 
macrophages, which are CCR2- CD11clo Ly6Clo. The second population is more abundant and 
derives from blood CCR2+ Ly6Chi monocytes. Following macrophage depletion, Ly6Chi 
monocytes can enter the myocardium, expand and reestablish a long-lasting population. In 
parallel, after depletion resident CCR2- macrophages also expand. After cardiac injury, IL-1b 
activation drives the expansion of the CCR2+ subsets and recruitment of CCR2+ monocytes, 
which once in the myocardium can differentiate into macrophages. The detrimental effects of 
macrophage expansion in cardiac injury are more likely due to the recruitment of circulating 
monocytes (Epelman et al., 2014). In AngII-induced hypertensive mouse models, circulating 
CCR2+ monocytes are expanded via AT1 signaling. In mice lacking CCR2, AngII-induced aortic 
inflammation and remodeling is completely abolished but no effects are seen on LV 
hypertrophy. These findings nonetheless suggest that CCR2+ monocyte expansion and 
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recruitment in the myocardium is detrimental in the cardiac injury (Ishibashi	   et al., 2004). 
Moreover, these studies suggest that the block of circulating monocytes, together with in situ 
expansion of resident macrophages, would lead to better outcomes in myocardial injury 
(Epelman	  et al., 2014). Rats with superrenal aortic constriction infused with CCL2 neutralizing 
antibody show a reduced macrophage presence in the myocardium, attenuated fibrosis and 
improved diastolic function (Kuwahara	  et al., 2004). CCL2 KO mice were refractive to AngII 
induced cardiac dysfunction; in fact these mice have reduced fibrosis in the myocardium, higher 
EF but absence of CCL2 did not affect ventricular remodeling (Haudek et al., 2010). All these 
studies together suggest that different cardiac macrophage populations have different functional 
roles and effects on cardiac injury. The recruitment via CCL2 of CCR2+ monocytes has a 
negative effect on fibrosis formation and inflammation, whilst resident population with 
phagocytosis capacity may be cardioprotective (Frieler and Mortensen, 2015). 
 
3.2.2 T cells 
 
The inflammatory response activated by heart stress leads, as already mentioned, to increased 
production of inflammatory cytokines that activate myoFb and recruitment and expand 
macrophages; T lymphocytes are also recruited into the myocardium and are involved in the 
pathophysiology of HF (Frieler and Mortensen, 2015; Fujiu  and Nagai, 2013). 
In recent years the involvement of immune cells in the pathogenesis of cardiovascular diseases 
has been intensively investigated. In TAC mice, in parallel to increased expression of 
chemokines such as CXCL16, CXCL10, CCL17, there is an increased infiltration of CD4 and 
CD8 T cells and APCs (CD11chi MHCIIhi). RAG2KO mice, that lack T and B cells, as well as 
CD8KO, CD4KO and MHCIIKO mice do not develop cardiac dilatation and preserve cardiac 
functionality when TAC is performed. The absence of HF induction in RA2KO can be reversed 
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by T cell administration. In the myocardium of RAG2KO mice, macrophage infiltration and 
fibrosis are also reduced (Laroumanie et al., 2014).  
T cells infiltrating TAC mouse myocardium show an increased expression of adhesion molecules 
ICAM-1, VCAM-1 and E-selectin. Tcra KO mice show a preserved heart functionality after 
TAC, reduced cardiac hypertrophy and reduced reactivation of fetal gene expression together 
with less fibrosis. Depletion of T cells with anti-CD3 antibody 48 hours after TAC led to a 
maintained cardiac contractility, reduced fibrosis but no effects on cardiac hypertrophy (Nevers 
et al., 2015).  
In two different models of hypertension, AngII and DOCA-salt induced, Rag1 KO did not 
develop high blood pressure. Adoptive transfer of T, but not of B cells, could restore the 
induction of hypertension in both models. AngII induces TNFα production and CD69 expression 
in T cells. Angiotensin receptor KO (At1r KO) T cell transfer into Rag1 KO recipients show that 
AngII has a small direct effect on T cells, both in activation and infiltration. Importantly, mice 
lacking T cells at the steady-state do no show significant differences in the blood pressure 
suggesting that T cells modulate hemodynamics only in the presence of pathological stimuli 
(Guzik et al., 2007).  
L-NAME-induced hypertension in C57BL76 mice, Balb/c and SCID show significant 
differences in the way the different strains respond to the model induction. C57BL/6 have a more 
predominant Th1 response whilst Balb/c have a Th2-biased T cell activation. Blood pressure did 
not significantly differ in the three strains whilst C57BL/6 SCID, that lack T cells, had the lowest 
heart stiffness and fibrosis; Balb/c mice showed increased fibrosis, tissue stiffness and fibrillar 
collagen crosslinking (Yu et al., 2006). In AngII-induced hypertension, Balb/c compared to 
C57BL/6 show a stronger decrease in heart functionality (EF and FS). Balb/c develop an 
eccentric hypertrophy in response to AngII, in contrast to C57BL/6 that develop a compensatory 
concentric cardiac hypertrophy. Moreover Balb/c in AngII-induced hypertension present more 
fibrosis in the myocardium (Peng et al., 2011). Another study of TAC-operated Rag1 KO mice 
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reported that there no difference in hypertrophy but increased perivascular fibrosis (Yang et al., 
2012).  
All of these studies taken together suggest that T cells have an active role in the mechanism 
underlying the pathogenesis of HF (Frieler and Mortensen, 2015). 
 
3.2.3 Treg cells in cardiovascular diseases 
 
Driven by the numerous studies cited in the previous section on inflammation and immune 
responses in HF, a consequent interest to find a way to inhibit these responses has been growing. 
As the natural controller of inflammation are Treg, several studies investigated the effects of 
Treg absence and Treg transfer in different cardiovascular pathologies (Meng et al., 2015). The 
majority of these studies focus their attention on myocardial infarction and atherosclerosis, 
whilst there are, nonetheless, some indications on Treg effects in cardiac hypertrophy and HF 
(Matsumoto et al., 2011; Tang	  et al., 2012; Weirather	  et al., 2014).  
Treg control the development of atherogenic plaques; depletion of Treg in atherosclerosis-prone 
ApoEKO mice leads to increased plaque inflammation and infiltration of T cells and 
macrophages; Treg presence also increases the stability of the plaque due to increased collagen 
deposition. TGFβ expression is essential for the Treg to exert their beneficial effects (Ait-Oufella 
et al., 2006). Hypertensive mice show an increased presence of apoptotic Treg and reduced IL-10 
(Matrougui et al., 2011). Treg transfer in hypertension mouse models infused with AngII or 
induced with L-NAME leads to a reduction in blood pressure and an improvement in endothelial 
relaxation of arteries accompanied by reduced T cell infiltration (Mian et al., 2016; Barhoumi et 
al., 2011). Arterial relaxation in hypertensive mice is restored by IL-10 produced by Treg. IL-10 
induces NADPH oxidase activity that increases eNOS activation and improves arterial 
relaxation. Infusion of IL-10 shows effects similar to Treg transfer in hypertensive mice (Kassan 
et al., 2011). In AngII-infused mice, Treg transfer not only reduces blood pressure but also 
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ameliorates cardiac damage, cardiac hypertrophy and fibrosis. Besides the effects on 
inflammation and infiltration, it is notable that Treg also have a beneficial effect on electric 
remodeling to which AngII mice undergo (Kvakan et al., 2009).  Finally one study shows the 
effects of Treg transfer in TAC mice, where -similar to the hypertension models- Treg are able to 
reduce inflammation, fibrosis and blood pressure (Kanellakis	  et al., 2011).  
 
3.4 Immunotherapies - Clinical trails with cytokine modifiers  
 
Considering the importance of the inflammatory response in the pathogenesis of HF and that, 
despite currently available therapies, HF in patients continues to progress unchecked, in recent 
years there have been several attempts to interfere with the response targeting proinflammatory 
cytokines. The choice of cytokines as targets was made in accordance with the cytokine 
hypothesis mentioned above (Mann, 2002). The cytokine hypothesis may be an oversimplified 
synthesis of the complexity of the inflammatory response within the ailing myocardium. 
Nevertheless several clinical trials have been conducted (Mann, 2015). Among biological 
modifiers targeting proinflammatory cytokines, the most promising results came from IL1b 
receptor antagonist anakinra. Anakinra produced encouraging results in a mouse model of 
myocardial infarction (mouse with LAD- left anterior descending artery- permanent binding). In 
this study, anakinra prevented adverse cardiac remodeling. Two small clinical trials in HF 
patients showed an increased exercise performance together with more oxygen consumption, but 
there are no data on cardiac dysfunction effects (Frieler and Mortensen, 2015; Mann, 2015). 
Effects of inflammatory mediators can be modulated via transcriptional or translational 
approaches, binding with soluble neutralizing antibodies or with antagonist of receptors. Clinical 
trials with TNFα blockers can be divided into two groups using two different types of biological 
modifiers: TNFα decoy receptor or a neutralizing monoclonal antibody. In the first case, 
circulating TNFα binds to the decoy receptors instead of TNFα-receptor attached to the cells 
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therefore preventing intracellular signaling; in the second approach, the neutralizing antibody 
eliminates circulating TNFα molecules. The decoy receptor for TNFα is etanercept: a 
recombinant fusion protein of the human p75 subunit of TNFα-receptor and Fc fraction of 
human IgG1. After short phase I trials, three different clinical trials were conducted on chronic 
HF patients: Randomized Etanercept North American Strategy to Study Antagonism of 
Cytokines (RENAISSANCE) in North America, Research into Etanercept Cytokine Antagonism 
in Ventricular Dysfunction (RECOVER) for Europe and Australia, and a third one, pooling 
together the data of both trails (Randomized Etanercept Worldwide Evaluation, RENEWAL). 
The trials were ended prematurely due to an evident lack of benefits, increased hazard risk for 
death, hospitalizing and worsening of HF. Since then, prescribing guidelines for etanercept have 
been changed suggesting caution when prescribing etarnercept to patients with HF (Mann, 2002; 
Yndestad et al., 2006). The Anti-TNFα Therapy Against CHF (ATTACH) with Infliximab, a 
chimeric monoclonal antibody of engineered murine Fab anti-human TNFα and human Fc from 
IgG1, underwent the same fatal results of the trials with etanercept. The ATTACH trial was 
terminated early due to increased deaths in the drug group of HF patients compared to placebo. 
As for etanercept, prescription guidelines now report that infliximab must be administered with 
caution to patients with HF. All these studies had negatively affected HF patients in dose and 
time-dependent manner (Mann, 2002). There are several reasons for the failure of anti-TNF 
therapies in clinical trails. Above all, the intrinsic cytotoxic effects of these drugs should be 
considered; for instance Infliximab binds to TNF and fixes complement in cells expressing 
TNFα, therefore causing cell death. In HF, cardiomyocytes express TNFα so infliximab could 
directly be cytotoxic for cardiomyocytes. Also it has been suggested that in setting such as HF, 
etanercept could act as agonist instead of antagonist. This hypothesis is sustained by the fact that 
etenercept binding TNFα stabilizes the cytokine. In rheumatoid arthritis (RA), the pathology for 
which etanercept has been developed, TNFα is encapsulated into the synovial joints and 
circulating levels are relatively low; in HF the stabilization of TNFα probably increases the 
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already high levels of circulating TNFα. TNFα exerts a plethora of effects on myocardium. 
Physiological levels of this cytokine can be cardio-protective since it is involved in tissue 
remodeling and repair; this could explain why the phase I trail in HF patients ended with good 
results (Mann, 2002; Hofmann and Frantz, 2013; Mann, 2015) The failure of these trials has 
brought more interest on immunomodulation as therapy for HF. The use of drugs that act on 
systemic inflammation show a higher therapeutic potential suggesting that targeting one single 
cytokine at the time is not the right approach, due to the redundancy of the functions of pro-
inflammatory cytokines (Yndestad et al., 2006; Hofmann and Frantz, 2013).  
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Figure B: Involvement of the immune system in the pathogenesis of HF. According to the 
cytokine hypothesis HF begins with the pro-inflammatory cytokines cascade that spreads to the 
circulation and exerts deleterious effects. Clinical trials with biological modifiers targeting TNFα 
and IL-1b have been conducted. Besides upregulation of pro-inflammatory cytokines, during HF 
there is an increase of chemokines (CCL2, CXCL10) and of TFGβ. CCR2+ macrophages are 
recruited and expend, CCL2 neutralizing antibody and Ccr2KO mice demonstrated that the 
recruitment of this population is detrimental for the myocardium. Inflammation drives fibroblasts 
activation, TGFβ type 1 receptor inhibitor is able to block fibrosis formation. T cells infiltrate the 
myocardium in absence of T cells in response to stress signals myocardium show better 
performance. Treg cells transfer has beneficial effects on HF mouse model.	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4. MATERIALS AND METHODS 
 
4.1 In vivo procedures 
 
All procedures were performed in compliance with national and EU legislation, and Humanitas 
Research Hospital regulations.  
 
4.1.1 Transverse Aortic Constriction 
 
TAC or sham for control group procedure was performed, according to (Rockman et al., 1997), 
on 8–10-week-old C57BL/6J male mice (Charles River, France) and on 8–10 week-old 
C57BL6/J Il10 KO (Jackson Laboratories, US) male mice. All animals, prior to operation, were 
screened via echocardiography to establish their baseline and to eventually remove outlier 
subjects. Mice were anaesthetized via intraperitoneal injection of a mixture of ketamine 
(100mg/kg) and xilazine (10 mg/kg). In order to access the aortic arch and perform the ligation a 
small incision at the level of the first intercostal space was performed. With the chest cavity open 
it was possible to isolate the aortic arch. The ligation was performed with an 8–0 prolene suture 
that was placed around the aorta and with a 27G needle. The ligation was Prolene suture was 
performed around the needle, which was immediately removed. The removal of the needle 
immediately produced a stenosis in the aortic lumen. The chest cavity was then closed with one 
6–0 nylon suture. All layers of muscle and skin were closed respectively with 6–0 continuous 
absorbable and nylon sutures. The sham control group underwent the same procedure with the 
exception of the final ligation. The induction of the model was then assessed measuring the 
differential gradient between the left and the right carotids, via echocardiography.   
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4.1.2 Echocardiography 
 
Prior to echocardiography analyses mice were shaved and weighted, all the weights data were 
recorder and used to calculate the ratios used for the assessment of cardiac hypertrophy. 
Echocardiography analyses were performed on mice under anesthesia with 1.0% isoflurane.  
The analyses were performed using a Vevo 2100 high-resolution in vivo imaging system 
(VisualSonics Fujifilm) with a MS550S probe "high frame" scanhead. Anesthetized mice were 
scanned for M-mode imaging. The pressure gradients were determined by echo Doppler on all 
animals that underwent TAC surgery and the induction of the model was considered for those 
animals with a gradient between 60 to 90 mm Hg. 
 
4.1.3 Abatacept treatment 
 
TAC and sham mice received the treatment with two different protocols. 
TAC and sham mice included in the early protocol study, starting 2 days after TAC or sham 
surgery, were intraperitonally injected with either 100 µl PBS or 200 µg CTLA4-Ig (abatacept) 
in 100 µl of PBS, three times a week, for up to 4 weeks. 
TAC mice included in the late protocol study, starting 2 weeks after TAC, were intraperitonally 
injected with either 100 µl PBS or 200 µg CTLA4-Ig (Abatacept) in 100 µl of PBS, three times a 
week, for up to 4 weeks. An additional group of TAC-operated mice received starting 2 days 
after surgery 200µg in 100µl of Human IgG Isotype Control (Novus) three times a weeks for 1 
week. 
An additional control group of mice did not undergo surgery and received 200 µg CTLA4-Ig 
(Abatacept) in 100 µl of PBS or 00µg in 100µl of Human IgG Isotype Control (Novus) three 
times a weeks for up to 4 weeks. 
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4.1.4 Adoptive transfer of wild-type B cells in Il10 KO mice 
 
Wild-type B cells were isolated from C57BL6/J male mice 10 weeks old. B cells were isolated 
via negative selection with B Cell Isolation Kit (Miltenyi Biotec). Total splenocytes were 
isolated; erythrocytes were lysated with Lysis Buffer (BD) and single cell suspension were 
counted and prepared for magnetic separation. Total splenocytes were labeled with a cocktail of 
biotinilated mouse antibodies for non-B cells and with anti-biotin microbeads. B cells from 
labeled single cell suspension were then purified on AutoMACS (Miltenyi Biotec) following 
“depletes” protocol. B cells were counted and purity was assessed staining with 1:100 anti-
mouse CD19 (eBio1D3, eBioscience), and analyzed by flow cytometry on FACS Canto II (BD 
Bioscience). Purity of B cells was > 90%. On day 0 C57BL6/J Il10 KO male mice received via 
intravenous injection 2•106 WT B cells. On day 1 the mice underwent echocardiographic 
baseline screening and on day 2 mice underwent TAC surgery. Starting 2 days after surgery, on 
day 4, mice were injected with 200 µg CTLA4-Ig (abatacept) in 100 µl of PBS, three times a 
week for 1 week. 
 
4.1.5 Adoptive transfer of wild-type T cells in Il10 KO mice 
 
Wild-type T cells were isolated from C57BL6/J male mice 10 weeks olds. T cells were isolated 
via negative selection with Pan T Cell Isolation Kit II (Miltenyi Biotec). Total splenocytes were 
isolated; erythrocytes were lysated with Lysis Buffer (BD) and single cell suspension were 
counted and prepared for magnetic separation. Total splenocytes were labeled with a cocktail of 
biotinilated mouse antibodies for non-T cells and with anti-biotin microbeads. T cells from 
labeled single cell suspension were then purified on AutoMACS (Miltenyi Biotec) following 
“depletes” protocol. B cells were counted and purity was assessed staining with 1:100 anti-
mouse CD3ε (145-2C11, BioLegend ) and analyzed by flow cytometry on FACS  Canto II (BD 
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Bioscience). Purity of T cells was > 90%. On day 0 C57BL6/J Il10 KO male mice received via 
intravenous injection 2•106 WT T cells. On day 1, mice underwent echocardiographic baseline 
screening and on day 2 mice underwent TAC surgery. Starting 2 days after surgery, on day 4, 
mice were injected with 200 µg CTLA4-Ig (abatacept) in 100 µl of PBS, three times a week for 
1 week. 
 
4.1.6 Transgenic Akt (Akt Tg) mice  
 
Male Akt –transgenic (Akt-tg) male mice, which constitutively overexpress the active E40K Akt 
mutant (Akt-E40K), as previously described in (Condorelli	  et al., 2002) and in the discussed in 
introduction (Section 1.3.1) were used at 8 weeks of age. WT age-matched littler mates were 
used as control. 
 
4.1.7 Exercise-trained mice  
 
Left ventricles of exercised mice and echocardiography analyses were kindly donated by Stolen, 
T. O. and Ormbostad Berre A. M.  Exercised and sedentary mice were BKS.Cg-m +/+ 
Lepdb/+db. These mice were heterozygous for the leptin receptor mutation but, when fed on a 
normal diet, display a wild-type metabolic phenotype. 8-week-old male mice included in the 
study were arbitrarily assigned to one of two groups: sedentary and exercise trained. This last 
group of mice was trained 80 minutes a day, 5 days a week, for 8 weeks, as previously described 
in (Stølen	  et al., 2009). Due to the difference in genetic background (BKS), all analyses of these 
mice were performed comparing them to their matching controls, so as to avoid genetic 
background-specific effects. 
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4.2 Human biopsies 
 
4.2.1 Patients with laminin A/C mutations  
  
All samples were obtained after informed consent according to the study protocols approved by 
the hospital’s ethics committee, as described previously Roncarati, R. et al. 
The severe cardiomyopathy patient samples (HF LVAD) were obtained from patients suffering 
from laminin A/C mutations, causing genetic form of dilated cardiomyopathy and heart failure 
(HF LVAD 1M). A second subset of patients carried a second mutation in titin (HF LVAD 2M), 
leading to a more severe dilated cardiomyopathy (Roncarati et al., 2013).  
 
4.2.2 Patients with aortic stenosis  
 
Ventricular samples of patients with aortic stenosis were obtained after informed consent. 
Samples were collected and fixed in 4% formalin at 4 °C overnight, samples were then paraffin 
embedded and sections of at 4µm were cut with Microtome (Microm). Sections were then used 
for aCD3e immunohistochemistry staining and Azan’s trichrome.   
 
4.3 Molecular biology 
 
4.3.1 Quantitative RT-PCR analysis 
 
Left ventricles were collected and snap frozen in liquid nitrogen, after collection samples were 
stored at −80°C until the RNA extraction. Tissues were homogenized in 1ml of PureZol RNA 
isolation reagent (Biorad) with GentleMACS and GentleMACS M Tubes (Miltenyi Biotec). 
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After tissue disgreagation the aqueous phase was isolated adding 200µl of chloroform (ratio 
chloroform/Trizol of 1:6). After collection of the aqueous phase 1.5 volumes of 100% Ethanol 
(EtOH) was added and immediately mixed. At this point the RNA was extracted using RNeasy 
Mini Kit (Qiagen) and the samples were added to the Qiagen Spin Column. RNA was then 
quantified with Nanodrop 2000c (Thermoscientific). The same amount of RNA was 
retrotranscribed with the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). 
Real-time qPCR reactions were performed using TaqMan Probes and TaqMan Universal Master 
Mix on a REALTIME AB 7900HT cycler (Applied Biosystems). The following TaqMan gene 
expression assays were used: Rn18S (Mm03928990_g1) as internal control, Cd3e 
(Mm005996484_g1), Foxp3 (Mm00475162_g1), Itgam (Mm00434455_m1), Tnfa 
(Mm00443260_g1), Il4 (Mm00445259_m1), Il17 (Mm00439618_m1), Ifng 
(Mm01168134_m1), Tgfb1 (Mm01227699_m1), Il10 (Mm00439614_m1), Il6 
(Mm00446190_m1), Il1b (Mm00434228_m1), Ccl2 (Mm00441242_m1), Ccl4 
(Mm00443111_m1), Ccl5 (Mm01302427_m1), Cxcl10 (Mm00445235_m1), Cxcl11 
(Mm00444662_m1).  
Expression of genes encoding for Brain Natriuretic Peptide (Nppb), Atrial Natriuretic Factor 
(Nppa), and Myosin heavy chain β (Myh7) was assessed (IDT) using Sybr Select Master Mix 
(Applied Biosystems) on a ViiA7 (Applied Biosystems) instrument.  




-Myosin ( Mhy7 ) 5’-CGCATCAAGGAGCTCACC-3’ 5’-CTGCAGCCGCAGTAGGTT-3’
Brain Natriuretic Peptide (Nppb ) 5’-GTCAGTCGTTTGGGCTGTAAC-3’ 5’-AGACCCAGGCAGAGTCAGAA-3’
Atrial Natriuretic Peptide (Nppa ) 5’-CACAGATCTGATGGATTTCAAGA-3’ 5’-CCTCATCTTCTACCGGCATC-3’
5’- GCTCTAGAATTACCACAGTTATCCAA -3’5’- AAATCAGTTATGGTTCCTTTGGTC -3’18S Ribosomal RNA (18S)
Primer list:
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4.4 Immunohistochemical analysis 
 
4.4.1 Samples collection and preparation  
 
Mouse heart samples were fixed in 4% formalin at 4 °C overnight, samples were then paraffin 
embedded and sections of at 4µm were cut with Microtome Leica.  
 
4.4.2 Azan’s trichrome 
 
The slides were stained with Azan’s trichrome for collagen (BioOptica). Sample sections on 
slides were deparaffinized and hydrated through a descending scale of alcohols. Slides were 
incubated in Azocarmine according to Heidenhain for 30 minutes at 56°C. Sections were washed 
in deionized water. Sections were than incubated in four different solutions without washing by 
adding 10 drops of each. At the end sections were rinsed in ascending alcohols scale. Slide 
images were digitalized and five fields for mouse sections and ten fields for human biopsies 
analyzed to quantify fibrosis, with an image analysis program (ImageJ). Cardiac fibrosis was 
calculated by measuring the percentage of Azan’s trichrome-stained area on the total myocardial 
area.  
 
4.4.3 CD3 immunohistochemistry on mouse heart samples 
 
Sample sections on slides were deparaffinized and hydrated through a descending scale of 
alcohols. Antigen retrieval was performed using DIVA (Biocare Medical). Sections were cooled 
and then washed with 1X PBS (Lonza) + 0.05% Tween 20 (Sigma). Endogenous peroxidase 
were blocked by incubation with Peroxidased I (Biocare Medical) for 20 min at room 
temperature (RT) and nonspecific sites were blocked with Rodent Block (Biocare Medical) 
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20’RT. The sections were then incubated for 1h at RT with rat anti-human CD3 (Serotec) diluted 
1:1000, washed, and incubated for 30 min at RT with RAT-on-mouse HRP polymer (Biocare 
Medical). Finally, sections were incubated with DAB (Biocare Medical), counterstained with 
hematoxylin, dehydrated through an ascending scale of alcohols and xylene, and mounted with 
coverslips using Eukitt (Fluka). All samples were observed and photographed with a microscope 
Olympus BX53 with a digital camera.  
 
4.4.4 CD3 immunohistochemistry on human heart biopsies 
 
Sample sections on slides were deparaffinized and hydrated through a descending scale of 
alcohols. Antigen retrieval was performed using W-Cap (Biocare Medical) at 98°C for 30 min. 
Sections were cooled and then washed with 1X PBS (Lonza) + 0.05% Tween 20 (Sigma). 
Endogenous peroxidase were blocked by incubation with Peroxidased I (Biocare Medical) for 20 
min at RT and nonspecific sites were blocked with Background Sniper (Biocare Medical) 20’RT. 
The sections were then incubated for 1h at RT with polyclonal rabbit anti-human CD3 (Dako) 
diluted 1:50, washed, and incubated for 30 min at RT with Envision +System HRP anti rabbit 
(Dako). Finally, sections were incubated with DAB (Biocare Medical), counterstained with 
hematoxylin, dehydrated through an ascending scale of alcohols and xylene, and mounted with 
coverslips using Eukitt (Fluka). All samples were observed and photographed with a microscope 
Olympus BX53 with a digital camera.  
 
4.4.5 TUNEL assay  
 
Sample sections on slides were deparaffinized and hydrated through a descending scale of 
alcohols and TUNEL assay was performed (Click-it plus TUNEL assay C10617,Life 
technology). Slides were incubated in 4% paraformaldehyde at 37°C for 15 minutes. Slides were 
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then washed and permeabilized with proteinase K solution for 15 minutes. Sections were fixed 
for 5 minutes in 4% paraformaldehyde at 37°C. Slides were rinsed in deionized water. The 
terminal deoxynucleotidyl transferase (TdT) reaction was then performed. TdT enzyme 
incorporates dUTP at the 3’-OH ends of fragmented DNA. dUTP conjugated with Alexa-Fluor 
488 was then detected and quantified. TdT Reaction buffer was added to each section, TdT 
enzyme and EdUTP were then added for 60 minutes at 37°C. Slides were rinsed in deionized 
water and washed in PBS 3% BSA 0.1% Titon X-100. Detection antibody was added and 
incubated. Samples digital images were acquired on fluorescent microscope Olympus IX53 with 
a digital camera and positive cells were counted.  
 
4.5 Cellular biology 
 
4.5.1 In vitro stimulation of splenocytes with Abatacept  
 
Total splenocytes were purified from spleens of 8-week-old C57BL/6J mice. Spleens were 
mushed on 70µm cell strainer; erythrocytes were lysated with lysis buffer (BD Bioscience) for 5 
minutes at room temperature. Plates were coated for 2 hours at room temperature with 2µg/ml of 
purified anti-mouse CD3ε (145-2C11, Biolegend). Splenocytes were culture with 20µg/ml 
Abatacept or 20µg/ml IgG isotype control (Novus) or nothing. After 72 hours of culture, 
Brefeldin A (eBioscience) was added during the last 4 hours of culture and splenocytes were 
prepared for flow cytometry analysis. 
 
4.5.2 In vitro stimulation of splenocytes with Abatacept after T cell depletion 
 
Total splenocytes were purified from spleens of 8-week-old C57BL/6J mice. Spleens were 
mushed on 70µm cell strainer; erythrocytes were lysated with lysis buffer (BD Bioscience) for 5 
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minutes at room temperature. Single cell suspensions were prepared for T cell isolation. T cells 
were depleted using Pan T Cell Isolation Kit II (Miltenyi Biotec) and AutoMACS (Miltenyi 
Biotec) as in 3.1.5. T cells purity and T cell depletion was assessed with 1:100 anti-mouse CD3ε 
(145-2C11, BioLegend) and analyzed with FACS Canto II (BD).  
Splenocytes T cell-depleted were plated and activated with 2µg/ml of anti-CD3 and 5µg/ml LPS 
(Sigma Aaldrich). To restore T cells after depletion T cells were added to T cell-depleted 
splenocytes and percentage of T cells was assessed with 1:100 anti-mouse CD3ε (145-2C11, 
BioLegend) and analyzed with FACS Canto II (BD). 
Total splenocytes or T cell-depleted splenocytes were stimulated with 2µg/ml of anti-CD3 and/or 
5µg/ml LPS (Sigma Aaldrich). Splenocytes were culture with 20µg/ml abatacept or no adds. 
After 48 of culture, Brefeldin A (eBioscience) was added during the last 4 hours of culture and 
splenocytes were prepared for flow cytometry analysis. 
 
4.5.3 In vitro experiments on neonatal cardiomyocytes 
 
Hearts were collected from 1–2 day old CD1 pups and digested with 0.5% of trypsine overnight 
at 4°C. Cardiomyocytes were then digested in 6% of collagenase II for 5 minutes at 37°C 
shaking. Six subsequent digestions were performed, digested tissues were then spinned and 
cardiomyocytes collected. To separate cardiomyocytes from fibroblasts single cell suspensions 
were pre-plated twice for 1 hour. Cardiomyocytes were than plated over 0.2% of gelatin and 
cultured in High Glucose DMEM (Lonza) with 25% of Medium-199 (Sigma-Aldrich), 1% 
Penicillin-Streptomycin (Lonza), 1% glutamine (Lonza), 10% horse serum (GIBCO) and 5% of 
fetal bovine serum (Euroclone). Cardiomyocytes under starvation were cultured High Glucose 
DMEM (Lonza) with 25% of Medium-199 (Sigma-Aldrich), 1% Penicillin-Streptomycin 
(Lonza), 1% glutamine (Lonza). After an overnight starvation cardiomyocytes were treated with 
100µM phenylephrine (PE) (Sigma Aaldrich) for 18. After 18 hours cardiomyocytes medium 
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was collected for ELISA assay and cells were harvested in PureZOL (Biorad) for RNA 
extraction and gene expression analysis of Nppa, Nppb and Mhy7. 
Cardiomyocytes cultured in presence of IL-10 and IL-6 were cultured with PE for 48 hours. Four 
hours after the addition of PE, 10ng/ml of either murine IL-6 (R&D Systems) or murine IL-10 
(Peprotech) or 20µg/ml of abatacept were added to the culture for 44 hours. Cardiomyocytes 
were harvested in PureZOL (Biorad) for RNA extraction and gene expression analysis of Nppa, 
Nppb and Mhy7. 
 
4.5.4 IL-6 ELISA Assay  	  Medium	   from	   neonatal	   cardiomyocytes	   cultured	   with	   100µM	   of	   PE	   for	   18	   hours	   were	  collected	   to	   perform	  Enzyme-­‐linked	   immunosorbent	   assay	   (ELISA)	   of	  mouser	   IL-­‐6	   using	  Mouse	   Il-­‐6	   ELISA	  Kit	   (R&D	   System	  DY406).	   ELISA	  was	   performed	   on	  Nunc-­‐Immuno	   96-­‐weel	  plates,	  coated	  with	  capture	  antibody	  overnight.	  After	  two	  washes	  plates	  were	  blocked	  adding	   reagent	   Diluent	   (PBS-­‐/-­‐	   1%	   BSA)	   for	   1	   hour	   at	   room	   temperature.	   	   Samples	   and	  standards	   were	   added	   to	   the	   plates	   and	   let	   incubate	   for	   2	   hours	   at	   room	   temperature.	  Detection	   antibody	   and	   then	   Streptavidin-­‐HRP	   were	   subsequently	   added.	   TMB	  (Thermoscientific)	  was	  added	  as	   substrate	   solution	  and	   to	   stop	   the	   colorimetric	   reaction	  H2SO4	  2	  N	  was	  added.	  Plates	  were	  acquired	  at	  Synergy	  H4	  at	  450nm.	  	  
 
4.5.5 Flow cytometry analyses  
 
Single cell suspension were obtained form spleens and lymph nodes mushing the tissues on 70 
µm cell strainers in cold PBS-/-. Erythrocytes were removed with lysis buffer (BD Biosciences) 
from spleen. Cardiac infiltrate was obtained from hearts after digestion with Liberase TM 
(Roche). Hearts were twice digested at 37°C for 10 minutes in agitation in RPMI-1640 medium 
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with 0.12% of Liberase. Erythrocytes were lysated with lysis buffer (BD Biosciences).  Cells 
from all the tissues were stained with Live/dead Aqua Fluorescent Reactive Dye (Life 
Technologies) diluted 1:1000 for 20 minutes at room temperature and Fc block was performed 
with anti-mouse CD16/32 (2.4G2, BD Pharmigen).  Extracellular marker stainings were 
performed at 4°C for 30 minutes in 2% FBS PBS-/- with anti-mouse CD45 (30-F11, 
eBioscience), anti-mouse CD3ε (145-2C11, BioLegend), anti-mouse CD19 (eBio1D3, 
eBioscience), anti-mouse CD11b (M1/70, Biolegend), CD11c (Bu15, eBioscience), F4/80 
(CI:A3-1, Serotec) in Figure 33, F4/80 (BM8, eBioscience) in Figure 26 and 27, Ly6C (HK1.4, 
eBioscience) or anti-CD25 PE (PC61.5, eBioscience).  
For intracellular staining Foxp3 / Transcription Factor Staining Buffer Set (eBioscience) was 
used. Samples were incubated for 1 hour at 4°C with Fixation/Permeabilization buffer, and were 
washed twice with Permeabilization Buffer. Anti-mouse IL-10 (JES5-16E3, eBioscience) and 
anti-mouse FoxP3 (FJK-165, eBioscience) were incubated for 1 hours at 4°C. Samples were 





Statistical analysis was performed in GraphPad Prism 5 (GraphPad Software 
Inc., San Diego, CA).. All data sets were tested for normal distribution prior to analyses. Normal 
distribution was tested using Kolmogorov-Smirnov test, D’Agostino and Pearson omnibus 
normality test and Sharpiro-Wilk normality test. Grubb’s test was performed in order to exclude 
spurious outliers on data sets without normal distribution. For two groups analysis with normal 
distribution statistical significance was tested using unpaired t-test. Statistical significance on 
more then two groups with normal distribution was assessed with either one-way ANOVA with 
Tukey post-test or two-way ANOVA with Bonferroni post-test. Statistical significance was 
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tested with Mann-Whitney test in two groups without normal distribution and with one-way 
ANOVA with Dunn’s post-test for analyses with more then two groups. Fisher’s exact tests were 
used in the analysis of collagen deposition, testing for the presence or absence of collagen stain. 
P-values shown refers to the following: *, p<0.5, **, p<0.01 ***,p<0.001, ns = not significant 
(p>0.05). 
  




The results described here are exclusively the work of the author; any assistance received is 
explicitly stated. For all cardiological mouse handling (echocardiography, TAC procedures), 
technical assistance was received from Mr P. Carullo of the Humanitas Cardiology Laboratory. 
For slide-based staining experiments (immunohistochemical staining for CD3 and Iba-1, 
collagen staining, TUNNEL assay) technical assistance was received from Dr C. Sardi and the 
Humanitas Immunohistochemistry Facility. 
 
5.1 Immunoprofiling of the inflammatory response in different models of cardiac 
hypertrophy 
 
It has become clear in recent years that inflammation plays an important role in the progression 
of HF. To better understand the pathogenesis of HF and identify potential novel therapeutic 
targets, we analyzed the inflammatory response in different cardiac hypertrophy models.  
 
5.1.1 Immunoprofiling a pathological cardiac hypertrophy model 
 
In order to investigate the inflammatory mediators involved in the pathological cardiac 
hypertrophy we utilized the TAC model, the standard model for this condition as mentioned in 
the Introduction (section 1.4.4). As control we utilized sham mice, both the procedures are 
described in Material and Methods (section 4.1.1). We analyzed the presence of cellular immune 
mediators and of soluble immune factors at 1 and 4 weeks after TAC surgery. 8 week-old 
C57BL6/J male mice underwent TAC or sham surgery after echocardiography analysis, in order 
to assess the heart functionality prior to disease induction, for every animal. At the moment of 
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sacrifice left ventricles (LV) were collected and total mRNA was extracted for gene expression 
analysis (Fig.1). As previously mentioned in the introduction, it has been shown that 
inflammatory cytokine production increases during cardiac hypertrophy and HF (Hofmann and 
Frantz, 2013); we confirmed the increase in the left ventricle at 1 week after surgery for Il6 and 
Tnfa in TAC-operated mice compared to sham. We also analyzed the expression of several 
chemokines. At this early timepoint, we found a significant increase of Ccl2, Ccl4, Ccl5, Cxcl10 
and Cxcl11. The increase of these cytokines and chemokines is an indication of a type 1 
(M1/Th1) polarization of the inflammatory responses. We also assessed the presence of cellular 
mediators; at 1 week, we found a significant increase of Itgam (Cd11b), which is a cellular 
marker for innate immune cells. Taken together, these results enable the speculation that the 
inflammatory response at 1 week is an innate immune even thought we cannot formally indicate 
which cells are mostly involved as CD11b is expressed by monocytes and macrophages. We can 
also speculated that is more prone towards a type 1 response as we detected an increase of TNFa, 
which is cytokine produced by immune cells polarized towards a type 1 response and 
chemokines that recruit cells that can be polarized towards a type 1 response (CCL2, CCL4, 
CCL5, CXCL10 and CXCL11). At 4 weeks post-TAC, we found an increase of Il4, which is one 
of the cytokines associated with a type 2 response. Moreover, we found a significant increase of 
Cd3e that is a marker for T cell presence. We speculated from these findings that at 4 weeks 
post-TAC, in the heart, we may have an involvement of not just innate but also adaptive immune 
responses. Simultaneously, the data are compatible with a switch of polarization from type 1 to 
type 2. The polarization of T cells towards a type 2 response has been reported to promote 
fibrosis formation (Wynn, 2004). The increase of Tgfb1 at 1 week in TAC-operated mice could, 
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We also analyzed the expression of Infg and Il17, cytokines respectively associated with Th1 and 







































































































































































































































































































































sham-control Transverse Aortic Constriction (TAC)
Figure 1: Characterization of the inflammatory response in left ventricle of a 
pathological cardiac hypertrophy model. Gene expression profile of soluble 
inflammatory mediators and immune cell markers in left ventricle of C57BL6/J male mice 
after TAC or sham surgery. Relative mRNA expression, via real-time qPCR, is normalized 
to 18s rRNA expression. 1 week after TAC Tnfa, Il6, Tgfb1, Ccl2, Ccl4, Ccl5, Cxcl10, 
Cxcl11 and Itgam (CD11b) were significantly increased in the TAC group compared to 
sham. Il4 and Cd3e were significnaly increased 4 weeks after surgery. White-bars 
represent sham-control mice and black bars represent TAC mice. Values are plotted as 
mean ± SEM (n=7-9). Two-way ANOVA, Bonferroni post-test: *, p-value <0.05; **, p-value 
<0.01; ***, p-value <0.001. 
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5.1.2 Immunoprofiling a physiological cardiac hypertrophy model 
 
We also analyzed the immune responses in two models of physiological cardiac hypertrophy, in 
order to examine their differences from pathological hypertrophy. We used a model of 
physiological hypertrophy induced by intense exercise and a genetic model. 
 
5.1.2.1 Exercise-induced physiological cardiac hypertrophy 
 
Physiological cardiac hypertrophy is characterized by an increase in the size of cardiomyocytes, 
accompanied by increased heart functionality (Stølen	   et al., 2009). We analyzed the gene 
expression of inflammatory mediators in the LV of exercised mice, compared to sedentary mice. 
In exercised mice we found no increase of any of the soluble mediators that characterize the 
inflammatory response of TAC mice (Fig.3). We did find a significant decrease of CCL2; as 
mentioned in the introduction, CCL2 in the myocardium is responsible for the recruitment of 
CCR2+ monocytes that can differentiate into macrophages (Ishibashi	  et al., 2004; Epelman et al., 
2014) and that can have detrimental effects in cardiac injury (Epelman	   et al., 2014). These 
Figure 2: Characterization of the inflammatory response in left ventricle of a pathological cardiac hypertrophy 
model. Gene expression profile of soluble inflammatory mediators and immune cell markers in left ventricle of C57BL6/J 
male mice after TAC or sham surgery. Relative mRNA expression, via real-time qPCR, is normalized to 18s rRNA 
expression. Infg, Il17 and il10 were not significantly different in the TAC group compared to sham at any timepoint. 
White-bars represent sham-control mice and black bars represent TAC mice. Values are plotted as mean ± SEM (n=7-
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findings suggest that, in this model of physiological cardiac hypertrophy, not only is heart 
functionality increased but the inflammatory response is absent. As fibrosis absence is a 
hallmark of physiological cardiac hypertrophy (Daskalopoulos et al., 2016), the absence of 
inflammation in these mice is compatible with the role of the immune response as a main driver 
for fibrosis.  
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Figure 3: Characterization of the inflammatory response in left 
ventricle of a physiological cardiac hypertrophy model. Gene 
expression profile of soluble inflammatory mediators and immune cell 
markers in left ventricle of exercised-trained mice (running) compared 
to sedentary. Relative mRNA expression, via real-time qPCR, is 
normalized to 18s rRNA. Tnfa, Il6, Ccl4, Ccl5, Cxcl10, Cxcl11, Il4, 
Itgam (CD11b) and Cd3e were not significantly expressed in 
exercised-trained mice compared to sedentary. Ccl2 significantly was 
decreased in the running mice. White bars are sedentary mice and 
black bars are exercised-trained (running) mice. Values are 
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5.1.2.2 Characterization of the inflammatory response in Akt-transgenic mice 
 
Akt-transgenic mice are C57BL6/J mice overexpressing a constitutively cardio-specific active 
form of Akt (E40K mutant Akt). Akt mice have increased myocardial mass and ameliorated 
heart functionality, thus can be considered an “artificial” form of physiological hypertrophy 
(Condorelli et al., 2002). We performed echocardiography analysis on Akt-tg and WT littermates 
at 8 weeks of age. Akt-tg mice presented a marked cardiac hypertrophy. Cardiac hypertrophy 
was assessed at sacrifice via the calculations of 3 ratios: heart weight / body weight (HW/BW), 
left ventricle weight / body weight (LW/BW) and heart weight / tibial length (HW/TL). These 
calculations are commonly used to measure heart augmentation in relation to the size of the 
mouse. Akt-tg mice displayed a significant increase in all three parameters (Fig.4).  
 
 
Figure 4: Assessment of AKT-transgenic mice cardiac hypertrophy.  
Heart weight body weight (mg/g), left ventricle body weight (mg/g) and heart weight tibia length (mg/cm) ratios in AKT-
transgenic (AKT-tg) mice compared to WT age-matched littermates display a significant increase in all these three parameters. 
White bars represent WT littermates and black bars represent AKT-tg mice. Values are plotted as mean ± SEM (n=6-7). 
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Echocardiography analysis of Akt-tg mice showed an increase in heart functionality, measured 
as fractional shortening (%FS) and ejection fraction (%EF) (Fig.5).  
 
 
Figure 5: AKT-tg have increased heart functionality. AKT-tg mice 8 weeks old have increased heart functionality compared 
to age-matched WT littermates. AKT-tg (black bars) have increased fractional shortening (%FS) and ejection fraction (%EF) 
compared to WT (white bars). Values are plotted as mean ± SEM (n=6-7). Unpaired t-test: **, p-value <0.01. 
 
 
We performed gene expression analysis for immune mediators in the left ventricle of Akt-tg 
mice and WT littermates (Fig.6). Akt-tg mice showed an increase in the expression of soluble 
mediators such as Ccl4, Ccl5, Cxcl10, Cd3e and Il4, compared to age-matched WT littermates. 
Akt-tg mice did also display a significant increase of cellular immune mediators. This is unlike 
exercise-trained mice, where a complete absence of an ongoing immune response was witnessed. 
This could be explained by the less “physiological” nature of the Akt-tg transgenic model 
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5.1.3 Neonatal cardiomyocytes in presence of phenylephrine produce IL-6 
 
We next wondered if the inflammatory response observed in pathological hypertrophy could be 
the result of cardiomyocyte responses to stress conditions. The cellular stress that characterizes 
pathological cardiac hypertrophy could trigger expression of inflammatory cytokines. As it has 
already been reported in the literature that cardiomyocytes are able to produce IL-6 (Ancey	  et al., 
2002), we first sought to confirm the expression of IL-6 in an in-vitro model of cardiac 
hypertrophy. We cultured neonatal murine cardiomyocytes (CM) with 100µM Phenylephrine 
(PE). PE, which is a α1-adrenergic receptor agonist, known to be potent inducer of hypertrophy. 
CM were cultured with PE and were collected for qPCR analysis. We found a significant 
Figure 6: Characterization of the inflammatory response in the left ventricle of a physiological cardiac 
hypertrophy model. Gene expression profile, via TaqMan real-time qPCR, of soluble inflammatory mediators and 
immune cell markers in left ventricle of 8-week-old Akt transgenic mice (Akt-Tg, black bars) (n=6) compared to wild-type 
mice (WT, white bars) (n=7). Bars represent relative mean mRNA expression internally normalized to 18s rRNA 
expression. The relative expression of Tnfa, Il6, Il1b, Tgfb1, Ccl2, Cxcl11, and the innate cell marker Itgam (CD11b) did 
not change in AKT-tg mice, whilst Ccl4, Ccl5, Cxcl10, Il4, and Cd3e were significantly increased. Values are plotted as 
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increase of IL-6 in CM after 8 hours of culture (Fig.7A). We also confirmed the presence of IL-6 
via ELISA of the culture medium of CM (Fig.7B).  
 
 
5.1.4 Inflammatory response in pathological cardiac hypertrophy recruits T cells into the 
myocardium 
 
5.1.4.1 T cells infiltrate the myocardium of TAC-operated mice  
 
As we found a significant increase of CD3e mRNA expression in TAC mice 4 weeks after 
surgery, we decided to further investigate the presence of T cells in the LV of TAC-operated 
mice. To confirm the mRNA findings, we evaluated, via immunohistochemistry (IHC) with anti-
CD3e, the presence of T cells in the myocardium of TAC- and sham-operated mice 4 weeks after 
surgery (Fig.8). We found a significant increase of T cell infiltration in TAC-operated mice 
compared to sham, confirming our gene expression data.  
Figure 7: IL-6 production by neonatal cardiomyocytes treated with Phenylephrine. Neonatal 
cardiomyocytes were cultured with 100uM of phenylephrine (PE). (A) IL-6 mRNA relative 
expression after 8 hours of culture assessed by TaqMan real-time qPCR, internally normalized to 
18s rRNA expression (n=3). (B) IL-6 protein production after 20h of culture, assayed by ELISA 
assay of the cell supernatants (n=6). Values are indicated as mean ± SEM. Unpaired t-tests. p 
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Having demonstrated the presence of T cells 4 weeks after the induction of the model, we 
hypothesized that T cells could potentially be detectable even at an earlier timepoint, even if 
their early presence would be too limited to lead to changes detectable by qPCR (see Fig 1). We 
thus assessed the presence of T cells 1 week after surgery, via IHC and we were able to detect 
the presence of few T cells in the myocardium of TAC-operated mice via immunohistochemistry 
(Fig. 9 A). Furthermore, we isolated infiltrating lymphocytes from single-cell cardiac 
suspensions via Lympholyte gradient purification, and performed flow cytometry analysis of 
CD3e+ cells (Fig.9 B). We could identify a small number of CD3e+ cells, thus further confirming 
that a small number of T cells is present as early as 1 week after TAC-surgery, before 
presumably expanding (or becoming further recruited) with the progression of the pathology.  
 
Figure 8: T cell infiltration in the myocardium of TAC-operated mice. Representative images of 
immunohistochemical staining (IHC) with anti-CD3e (brown color) of left ventricle of sham- and TAC-
operated C57BL6/J mice 4 weeks after surgery and statistical analysis of the number of positive CD3e cells. 
Original magnification of the images 10X; bars = 200 µm. White bar represent sham-mice and black bar 
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5.1.4.2 Correlation between T cell presence and inflammation 
  
We next wondered whether the presence of inflammation correlated with T cell infiltration. Any 
such correlation would be compatible with the inflammation acting as the driver for T cell 
recruitment or expansion.  To assess this, we correlated CD3e mRNA expression (as a proxy for 
the presence of T cells) with IL-6 mRNA expression (as a proxy for cardiac inflammation), 
assuming a linear regression model (Fig.10). TAC-operated mice 4 weeks after surgery did show 
a significant positive slope suggesting the existence of a correlation between inflammatory 
Figure 9: Presence of T cells is 
detectable in TAC-operated mice 
starting 1 week after surgery. (A) 
Immunohistochemical staining with anti-
CD3e (brown coloration) in TAC-operated 
mice 1 week post-operation. Original 
magnification 10X; bar = 200µm (B) 
Representative plot of flow cytometry 
analysis of CD3e+ cells isolated from heart 
of TAC mice 1 week after operation. 
B 
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cytokine expression and T cell infiltration in the myocardium. Each red circle represents one 
mouse included in the study and the red line shows the linear regression. Sham-operated mice 4 
weeks after surgery also showed a significant correlation between IL-6 expression and T cell 
infiltration, although with lower values for both parameters. A low-grade inflammation is likely 
to be present in the myocardium of sham mice as a result of the (invasive, but lacking aortic 
ligation) sham surgery. This would confirm that sham-operation is the correct control for the 
TAC model, as it controls for any non-cardiac inflammatory components. The results of the 
correlation show that T cells could be recruited even by a low-grade inflammation, though 
obviously resulting in lower overall numbers, as shown in figure 8.  
  
Figure 10: Correlation between relative mRNA expression of IL-6 and CD3e in 
left ventricles of sham- and TAC-operated mice. Each red circle represents one 
C57BL6/J TAC-operated mouse 4 weeks after surgery (n=9). Red line is the linear 
regression between Cd3e and Il6 expression. Each blue square represents a sham-
operated mouse 4 weeks after surgery (n=7) and blue line is the linear regression 
between Il6 and Cd3e expression. Linear regression test; p value = 0.0002 for TAC-
mice ,p value = 0.0037 for sham mice. 
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5.1.4.3 T cell infiltration in human biopsies of HF patients 
 
In order to verify the clinical relevance of our findings, we performed IHC analysis of T cell 
infiltration in human biopsies of patients with two different forms of HF. Due to the nature of 
these biopsies the number of patients for this analysis is low, yet still significant.  
First we examined the left ventricle biopsies of patients carrying laminin A/C mutations, which 
lead to a genetic form of dilated cardiomyopathy, as well as from patients with an additional 
mutation in tinin, leading to an even more severe form of cardiomyopathy. Laminin and tinin are 
both contractile and structural proteins of the sarcomeres (Roncarati et al., 2013). These biopsies 
were obtained during surgery for the implantation of Left Ventricular Assist Devices (LVAD). 
This genetic form of HF is not caused by infection or autommunity, thus any sign of 
inflammation would confirm that an immune response is associated to the cardiac pathology per 
se. T cells in the LV of patients with 1 mutation (LVAD 1M) were significantly more abundant 
compared to healthy donors. Patients with 2 mutations (LVAD 2 M) showed an even greater 
infiltration of T cells (Fig.11). The presence of T cells in the myocardium thus positively 
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These biopsies we also analyzed for the presence of fibrosis via Azan’s trichrome staining. The 
results obtained for the analysis of the presence of fibrotic tissue in the biopsies reflected the 
same trend as those obtained for T cell infiltration. Indeed, patients with HF of both groups had a 
higher percentage of fibrosis compared to healthy donors and also, as for T cell infiltration, there 
was a positive linear trend with increasing severity of the condition (Fig.12).  
 
Figure 11: T cell infiltration in human cardiac biopsies of a genetic form of HF. Representative images of anti-CD3e 
staining (brown coloration) of left ventricular biopsies from patients with severe dilated cardiomyopathy due to a mutation 
in lamin A/C (HF LVAD 1M) (n=4), and patients carrying a second mutation in titin (HF LVAD 2M) (n=2) patients 
compared to healthy ventricles (n=3).. All the biopsies were obtained prior to Left Ventricular Assist Device (LVAD) 
placement. Number of positive CD3e cells are plotted as mean ± SEM for each group analyzed. One-way ANOVA with 
Dunn’s post-test: *, p-value <0.05. 




































Patients with laminin mutations suffer from HF with a reduced ejection fraction (HFrEF). This is 
matched by the cardiac pathology in TAC-operated mice. However, the initial stimulus in the 
TAC model is pressure overload. Thus, to further assess the clinical relevance of our findings, 
we analyzed a second group of patients with aortic stenosis, which can lead to HF (Ross and 
Braunwald, 1968). Patients with aortic stenosis develop HF induced by pressure overload, hence 
sharing the etiology of their cardiac dysfunction with the TAC model. We found that patients 
Figure 12: Collagen quantification in human cardiac biopsies of a genetic form of HF. Representative images of 
Azan’s trichrome staining (blue coloration) of left ventricular biopsies from patients with severe dilated cardiomyopathy 
due to a mutation in lamin A/C (HF LVAD 1M) (n=4), and patients carrying a second mutation in titin (HF LVAD 2M) 
(n=2) patients compared to healthy ventricles (n=3). All the biopsies were obtained prior to Left Ventricular Assist Device 
(LVAD) placement. Percentage of collagen of 10 ROIs for each biopsy are plotted as mean ± SEM. Fisher’s exact test 
for the presence versus absence of fibrosis: *, p-value <0.05; **, p-value <0.01. The amount of collagen significantly 
correlated with the severity of disease (one-way ANOVA with post-test for linear trend: p<0.001). 
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with aortic stenosis did indeed have increased levels of T cells infiltrating the left ventricle, as 
well as displaying significantly augmented presence of fibrosis (Fig.13).  
 
These findings, taken together, support the hypothesis that a connection between T cells and 
fibrosis exists in pathological cardiac hypertrophy. 
 
5.2 Therapeutic approach in PO-induced HF 
 
Our mRNA expression analysis results and the immunohistochemical analysis of T cell 
infiltration, in both mouse models and in patients, suggest that pathological HF is characterized 
by T cell presence. In the past the inhibition of inflammation in HF patients has been attempted 
via the use of biological modifiers targeting pro-inflammatory cytokines (Mann, 2002). Since 
this approach failed, most likely due to the redundancy of cytokine functions, we hypothesized 
that using T cells, as therapeutic target could possibly be a more promising target, enabling a 
greater control of inflammation. T cells are required for the maintenance of long-term immune 
responses. Hence inhibiting T cell function could be a promising therapeutic strategy. One way 
Figure 13: Collagen and T cells quantification in cardiac human biopsies of 
patients with aortic stenosis. (A) Cardiac biopsies of healthy ventricles (white bars, 
n=3) and patients with aortic stenosis induced-HF (black bars, n=2) stained with 
Azan’s trichrome. Statistical analysis of the percentage of collagen in ROIs. Values 
are expressed as mean ± SEM. Fisher’s exact test for presence or absence of 
collagen. ***, p-value <0.001. (B) Cardiac biopsies of healthy ventricles (white bars, 
n=3) and patients with aortic stenosis induced-HF (black bars, n=2) stained with anti-
CD3e. Statistical analysis of the number of CD3e+cells. Values are expressed as 
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of controlling T cell function is via the adoptive cell transfer of Treg, which has already been 
performed in TAC-operated mice with encouraging results (Kanellakis	  et al., 2011). We could 
detect a significant increase of Foxp3 expression in the myocardium of TAC mice 8 weeks after 
TAC-surgery (Fig.14). The increase in Foxp3 indicates the presence of Treg; we hypothesized 
that, as in other immunological contexts (Garetto	   et al., 2015), Treg recruitment could be an 
attempt of the immune system to block an unwanted immune response.  
 
 
As adoptive cell therapy is still in need of substantial development before becoming widely 
applicable in the clinic, we decided to intervene by inhibiting T cell function via the use of 
reagents that are currently approved for clinical use. We chose to use a reagent derived from 
molecules naturally used by Treg to control inflammation, CTLA4. We injected TAC-operated 
mice with the FDA-approved drug CTLA4-Ig (abatacept). Abatacept has been already discussed 

































Figure 14: increase of regulatory T cells in TAC-operated mice. Gene expression 
analysis, via real-time TaqMan qPCR, of Foxp3 internally normalized on 18s rRNA in 
the left ventricle of C57BL6/J mice TAC- and sham-operated. Foxp3, Treg specific 
marker, significantly increase in TAC mice 8 weeks after surgery. White bars represent 
sham-opertaed mice and black bars TAC-operated mice. Values are plotted as mean ± 
SEM (n=7–9). Two-way ANOVA with Bonferroni post-test; *, p-value <0.05. 
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5.2.1 Inhibition of T cell costimulation preserves heart functionality in TAC-operated mice  
 
 TAC-operated mice 2 days after surgery already show significant changes in cardiac function 
(Souders	   et al., 2012). We assessed the T cell activation at this early timepoint in the heart-
draining lymph nodes. We analyzed the median fluorescence intensity (MFI), via flow 
cytometry, of the T activation marker CD25 among CD3e+ cells in heart-draining lymph nodes 
(mediastinal lymph nodes), non-draining lymph nodes (inguinal lymph nodes) and spleen. We 
found a significant upregulation of CD25 on T cells in the mediastinal lymph nodes (Fig.15).  
 
 
Accordingly, we decided to start the treatment with abatacept at 2 days after TAC-operation, as 
this was the earliest timepoint in which the pathology is macroscopically measurable and the 
target of our treatment (activated T cell-dependent processes) is present. To this end, 8 week old 
C57BL6/J male mice, after pre-treatment echocardiography screening, underwent TAC or sham 
surgery. Starting 2 days after surgery, the mice were injected for 4 weeks, 3 times a week, with 
200 µg of abatacept, resuspended in 100 µl of PBS or with 100µl with PBS (Fig.16).  In a 













































Figure 15: T cell activation occurs 2 days after TAC-operation in heart-darining lymph 
nodes. T cell activation in mediastinal (heart-draining) lymph nodes, inguinal lymph nodes and 
spleens of sham- (white bars, n=4) or TAC-operated (black bars, n=4) 2 days after surgery 
analyzed via flow cytometry. The mean fluorescence intensity (MFI) of CD25 expressed by CD3e+ 
live T cells is plotted as mean ± SEM. Unpaired t-test. *, p-value <0.05.  
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in order to verify whether the effects of the drug on the progression of the disease could be 
achieved when the ailment was already at a more advanced state. 
 
 
5.2.1.1 Assessment of heart functionality after early treatment  
 
TAC- and sham-operated mice were monitored via echocardiography for the duration of the 
experiment. Mice from all groups did not display significant differences at the baseline for all the 
echocardiographic parameters analyzed (Fig.17). As expected, starting from week 1, TAC-mice 
injected with PBS had a significant reduction of %FS and %EF compared to PBS-injected sham 
controls. In abatacept-injected TAC mice, on the contrary, no difference at 1 and 4 weeks 
compared to sham-operated mice was observed. Abatacept-injected TAC mice showed a 
transient but significant difference compared to sham controls at 3 weeks after operation; 
however this difference, was lost by 4 weeks. Furthermore, there was a significant difference in 
%FS and %EF between abatacept-injected and PBS-injected TAC-operated mice. The difference 
in %FS between abatacept-injected and PBS-injected TAC-operated mice was evident starting at 
1 week post-operation whilst the significance of difference in %EF between these two groups 
increases over time. The beneficial effects of abatacept on the myocardium were evident also in 
other echocardiography parameters, such as end-diastolic left ventricular internal diameter 




100µl of PBS 3 TIMES A WEEK
200 µg of the drug in 100µl of PBS 3 TIMES A WEEK
ECHOCARDIOGRAPHY ECHOCARDIOGRAPHY ECHOCARDIOGRAPHY
s
Figure 16: schematic representation of the therapeutic protocol applied to TAC-operated mice. C57BL6/J 
8-10 weeks old male mice were screened via echocardiography. Starting 2 days (for the early treatment protocol) 
or 2 weeks (for the late treatment protocol) after surgery mice received 200µg of Abatacept in 100µl of PBS or 
100µl of PBS 3 times a week for up-to 4 weeks. Heart functionality was analyzed via echocardiography during 
the duration of the experiment.  
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(LVIDd) and end-systolic left ventricular internal diameter (LVIDs). These results suggest that 
abatacept administration reduces cardiac dysfunction and delays the progression induced by 
pressure-overload. The effects on heart functionality may seem of small magnitude but it has an 
important effect due to the crucial role of heart pump function for the survival of the organism. 
Even a small decrease in percentage can have a negative and important effect on the quality of 
life of the individual. 
Figure 17: Abatacept reduces cardiac dysfunction and delays the progression induced by 
pressure-overload. C57BL6/J male mice, starting 2 days after sham- or TAC-operation, 
received three times per week 200µg of abatacept or PBS, for 4 weeks. At baseline, 1, 3 and 4 
weeks after operation Fractional Shortening (A, %FS), Ejection Fraction (B, %EF), Left Ventricle 
Internal Dimension in Diastole (C, LVIDd) and Left Ventricle Internal Dimension in Systole 
(LVIDs) were measured via echocardiography. In the graphs are plotted the mean ± SEM (n=7–
9) for each experimental group. Two-way ANOVA with Bonferroni post-test was applied and p-
values are shown in the panel.  
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5.2.1.2 Assessment of heart functionality after late treatment 
 
We performed echocardiography analyses on TAC-operated mice that received their first 
abatacept treatment 2 weeks after surgery, in order to assess the effects of the drug on more 
advanced-stage cardiac pathology. The late administration of abatacept did indeed have 
significant beneficial effects on heart functionality. As the treatment started 2 weeks after the 
TAC operation, heart functionality was already reduced compared to the baseline, yet in 
abatacept-treated TAC-operated mice further reduction in heart functionality was blocked. %FS 
and %EF of abatacept-treated mice were significantly different compared to PBS-treated mice, 
thus suggesting that abatacept is able to delay pressure overload-derived detrimental effects on 




























Weeks post-TAC Weeks post-TAC
***
***
0 2 4 weeks
abatacept treatment
LATE TREATMENT
0 2 4 weeks
abatacept treatment
LATE TREATMENT
Figure 18: Abatacept treatment starting 2 weeks after operation improves FS and EF. 
C57BL6/J male mice, starting 2 weeks after TAC-operation, received three times per week 200µg 
of abatacept or PBS, for 2 weeks. At baseline, 2 and 4 weeks after operation Fractional 
Shortening (A, %FS) and Ejection Fraction (B, %EF) were measured via echocardiography. In the 
graphs are plotted the mean ± SEM (n=7) for each experimental group. Two-way ANOVA with 
Bonferroni post-test. ***; p-value < 0.001. 
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The beneficial effect on LVIDs was also maintained with the late treatment protocol whilst 




5.2.2 Assessment of heart hypertrophy after abatacept treatment   
 
Besides impaired heart functionality, cardiac hypertrophy is one of the key features of HF in the 
TAC mouse model. Focusing on the early-treatment protocol, we examined the hypertrophic 
state of the TAC-operated mice at the end of the fourth week post-surgery. At this timepoint, we 
weighed the whole heart and the left ventricle post-sacrifice, so as to calculate the ratios 
HW/BW, LW/BW and HW/TL, as indicators of cardiac enlargement (Fig.20) (see above, section 
5.1.2.2).  For two of these morphometric parameters, HW/BW and HW/TL, abatacept-treated 
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LATE TREATMENT
Figure 19: Effects of abatacept treatment starting 2 weeks after operation on LVIDd and 
LVIDs. C57BL6/J male mice, starting 2 weeks after TAC-operation, received three times per week 
200µg of abatacept or PBS, for 2 weeks. At baseline, 2 and 4 weeks after operation Left Ventricle 
Internal Dimension in Diastole (A, LVIDd) and Left Ventricle Internal Dimension in Systole (B, 
LVIDs) were measured via echocardiography. In the graphs are plotted the mean ± SEM (n=7) for 
each experimental group. Two-way ANOVA with Bonferroni post-test. *; p-value < 0.05. 
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treated mice. LW/BW of abatacept-injected TAC mice was not different compared to PBS-
treated TAC-operated mice; we speculate that the left ventricular growth in the two groups of 




Moreover we also analyzed gene expression, via qPCR, of genes belonging to the fetal gene 
program that is commonly reactivated in pathological cardiac hypertrophy (Dirkx	  et al., 2013) 
(Fig.21). Mhy7, Nppb and Nppa upregulation in TAC-operated mice treated with PBS was 
significantly increased compared to sham control; this upregulation was not present in abatacept-














































































Figure 20: Heart hypertrophy is limited by abatacept administration in TAC-operated mice. TAC-operated mice 
injected, starting 2 days after operation, with abatacpet or PBS were sacrificed after 4 weeks. Ratios of (A) heart weight 
body weight (HW/BW, mg/g), (B) left ventricle body weight (LW/BW, mg/g) and (C) heart weight tibia length (HW/TL, 
mg/cm). Values are plotted as mean ± SEM (n=5-7). White bars represent TAC-operated mice injected with abatacept. 
Black bars represent TAC-operated mice injected with PBS. Unpaired t-test: *, p-value <0.05 
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5.2.3 Analysis of fibrosis and cardiac infiltration in TAC mice treated with abatacept 
 
To further investigate the effects of abatacept on TAC-operated mice, we evaluated the fibrosis 
present in the myocardium, as fibrosis is one of the main features that distinguish pathological 
cardiac hypertrophy from physiological cardiac hypertrophy. Moreover, we examined the 
presence of immune cells infiltrating the myocardium after the treatment. 
 
5.2.3.1 Abatacept inhibits fibrosis formation in the myocardium of TAC-operated mice 
 
To achieve this, at the end of the fourth week of experiments (using the early treatment 
protocol), mice were sacrificed and hearts were collected for histological analyses. Hearts were 
paraffin-embedded and slides were cut longitudinally along the heart, in order to enable full view 
of the 4 chambers of the organ. We then stained with Azan’s trichrome to enable analysis for 
fibrosis. Collagen staining intensity in abatacept-treated TAC-operated mice did not show 












































































Figure 21: Fetal gene program reactivation is blunted in TAC-operated mice after abatacept treatment. TAC-
operated mice were injected, starting 2 days after operation, with abatacpet or PBS for 4 weeks. Relative gene 
expression, in left ventricles, of (A) β-myosin (Mhy7), (B) brain natriuretic peptide (Nppb) and (C) atrial natriuretic 
factor (Nppa) were analyzed by real-time qPCR and internally normalized to 18S. Values are plotted as mean ± SEM 
(n=4-7). Two-way ANOVA with Bonferroni post-test; *, p-value <0.05; **, p-value <0.01. White bars represent sham 
mice and black bars represent TAC-operated mice.  
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significant increase in fibrosis in the myocardium. Abatacept treatment was thus able to block 
cardiac fibrosis formation. (Fig.22). 
 
5.2.3.2 Abatacept administration reduces heart infiltration of T cells and macrophages 
 
Infiltration of the myocardium by immune cells has been shown to have detrimental effects on 
cardiac injury and repair, also is associated with fibrosis and cardiomyocytes apoptosis. 
Abatacept targets CD80/CD86, the ligands for CD28, which are necessary for T cell 
costimulation (Sharpe, 2009). As abatacept is known to block T cell activation, we wondered if it 
affected T cell accumulation in the ailing myocardium. We analyzed, via IHC with anti-CD3e, 
hearts of TAC mice, at 4 weeks after TAC operation, having undergone treatment with either 






























Figure 22: Abatacept administration reduces fibrosis in myocardium of TAC-
operated mice. Sections of heart of sham- or TAC-operated mice, 4 weeks after 
operation and abatacept or PBS administration, were stained with Azan’s trichrome 
(n=2). Five ROIs were selected in each sample and collagen staining intensity was 
quantified by image acquisition software. In the graphs each point represents the 
percentage of collagen in each ROI analyzed. The red lines represent the mean of 
each experimental group. The dotted red line is the threshold between collagen 
positive and negative ROIs. Fisher’s exact test for the presence or absence of 
fibrosis was applied to sham versus TAC-operated for each treatment group. *, p-
value<0.05. 
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significantly lower compared to PBS-treated mice. This suggests that T cell recruitment and/or 
expansion that occurs during the progression of TAC towards HF is blunted by the 




Figure 23: Abatacept reduces T cell expansion in the myocardium of TAC-operated 
mice. Hearts of TAC-operated mice treated with abatacept or injected with PBS were stained 
with anti-CD3e 4 weeks after operation. Statistical analysis was applied on number of CD3e+ 
cells; data are plotted as mean ± SEM (n=2). White bar represents TAC-operated mice treated 
with abatacept and black bar represents TAC-operated mice injected with PBS. Unpaired t-
test; *, p-value < 0.05. Representative images of the immunohistochemical staining with anti-
CD3e (brown coloration; original magnification 40X; scale bar = 50 µm).  
 
TAC Abatacept TAC PBS















TAC Abatacept TAC PBS















TAC Abatacept TAC PBS















	   96	  
One of the known mechanisms of action of abatacept is the inhibition of T cell-dependent 
activation of monocytes and macrophages (Cutolo et al., 2009). T cells receive costimulation via 
CD80/CD86 and can thus subsequently enhance the activation of APC cells, including B cells, 
monocytes and macrophages. We thus analyzed, via IHC, the presence of AIF-1+ cells in TAC-
operated mice, 1 week after operation (Fig.24). AIF-1 (Iba-1) is a marker for T cell-depednent 
macrophage activation (Utans et al., 1995). The presence of macrophages 1 week after TAC is 
consistent with our gene expression analysis showing an increase of CD11b, which is a marker 
for monocytes and macrophages, at the same timepoint. Abatacept administration significantly 
reduced the presence of macrophages in the myocardium of TAC-operated mice.  
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Figure 24: Abatacept inhibits macrophages infiltration in hearts of TAC-operated 
mice. Hearts of TAC-operated mice treated with abatacept or injected with PBS were 
stained with anti-AIF-1 (Iba-1) 1 week after operation. Statistical analysis was applied on 
number of AIF-1+ cells; data are plotted as mean ± SEM (n=2). White bar represents 
TAC-operated mice treated with abatacept and black bar represents TAC-operated mice 
injected with PBS. Unpaired t-test; **, p-value < 0.01. Representative images of the 
immunohistochemical staining with anti-AIF-1 (brown coloration; original magnification 
20X; scale bar = 100 µm). 
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At 4 weeks after TAC, the difference in percentage of macrophages in the myocardium was not 
significant (Fig.25); these results match the reduction in CD11b expression between 1 and 4 
weeks, as identified in our mRNA expression assays  
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Figure 25: Macrophage presence in the myocardium of TAC-operated mice treated 
with abatacept does not change after 4 weeks. Hearts of TAC-operated mice treated 
with abatacept or injected with PBS were stained with anti-AIF-1 (Iba-1) 4 weeks after 
operation. Representative images of the immunohistochemical staining with anti-AIF-1 
(brown coloration; original magnification 20X; scale bar = 100 µm). Statistical analysis 
was applied on number of AIF-1+ cells; data are plotted as mean ± SEM (n=2). White bar 
represents TAC-operated mice treated with abatacept and black bar represents TAC-
operated mice injected with PBS. Unpaired t-test.  
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5.2.3.3 Analysis of monocyte and macrophage maturation in the myocardium 
 
In order to further characterize the macrophages and monocytes infiltrating the myocardium, we 
sought to identify and distinguish, via flow cytometry analysis, the different populations present. 
At 1 week after surgery, hearts of TAC-operated mice treated with abatacept or PBS were 
collected and single cell suspensions were stained for flow cytometry analysis.  
We identified the cell populations via side and forward scatter gating, followed by identification 
of single cell populations. We then discriminated dead from live cells using the a cell viability 
dye. Finally we detected the CD45+ population in our samples. In order to distinguish the 
different degrees of maturation, ranging from monocytes to mature macrophages, we identified 
among the CD45+ CD11b+ cells three distinct populations: Ly6Chi F4-80- monocytes, Ly6Chi F4-
80+ maturing macrophages and finally Ly6C- F4-80+ mature macrophages (Fig.26) (Epelman	  et 
al., 2014).  
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In PBS-treated mouse hearts, the mature population was significantly higher whilst the immature 
significantly lower, whilst the opposite was true in abatacept-treated mouse hearts. These results 
suggest that abatacept is able to limit transition from immature monocytes to mature 
macrophages in the myocardium (Fig. 27), though we cannot formally distinguish this effect 
from a differential recruitment of the two populations. 
CD45+ CD11b+CD45+live cells
single cells






























































Figure 26: Gating strategy for flow cytometry analysis of macrophages infiltrating the 
myocardium.  Cardiac single cell suspensions from TAC operated mice 1 week after operation were 
stained for flow cytometry. Cells were first gated based on forward (FSC) and side scatter (SSC), 
doublets were excluded and live single cells were discriminated from dead cells using Live/Dead dye. 
Among single live cells CD45+ and CD11b+ cells were selected. Further discrimination was based on 
Ly6C and F4-80 expression: Ly6C+ F4-80- monocytes, Ly6C+ F4-80+ immature macrophages and 
Ly6C- F4-80+ mature macrophages. 
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5.2.4 Administration of human IgG Isotype has no effects on murine heart functionality, whilst it 
has detrimental effects on TAC-operated mice cardiac contractility 
 
Abatacept is a fusion protein of human CTLA4 and human IgG immunoglobulin. Although it has 
been shown to have effects on mouse models (Dhirapong et al., 2013), we performed additional 
controls in order to assess if abatacept could have immunogenic effects on mice.  
A group of non-TAC-operated mice received abatacept, using the same administration protocol 
applied to the experimental group. Moreover, we also injected another group of non-operated 
mice with human IgG isotype control, to verify if the human immunoglobulin portion per se 
could have negative effects on mice. Neither of these two groups of mice showed a significant 
change in heart functionality compared to sham-operated, untreated mice (Fig.28).  Thus the 
administration of abatacept per se had no effects, beneficial or detrimental, on heart 
functionality. Moreover abatacept is a human fusion protein with an extracellular portion of a 
A B















































Figure 27: Abatacept inhibits cardiac macrophage maturation. 
Cardiac single cell suspensions of TAC operated mice treated with 
abatacept or injected with PBS 1 week after the operation were 
stained and analyzed by flow cytometry. Cells were gated as in 
Fig.26. Percentage of (A) F4-80+ Ly6C+ out of CD11b+ CD45+ live 
cells and (B) percentage of F4-80+ Ly6C- out of CD11b+ CD45+ live 
cells are plotted as mean ± SEM. Black circles represent TAC-
operated mice injected with abatacept and black squares represent 
TAC-operated mice injected with PBS. Unpaired t-test; *, p-value < 
0.05; **, p-value < 0.01 (n=4, 3). 
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human IgG1. The lack of effects on heart functionality in non-TAC-operated mice injected with 
IgG isotype control suggested that even if abatacept is a human molecule it is well tolerated by 
mice.  
 
However, when we administered IgG isotype control to TAC-operated mice, the outcome was 
worsened heart functionality; as early as 1 week after TAC, IgG-injected TAC mice had a 
significant decrease in %FS and %EF compared to PBS-injected TAC-operated mice. The worse 
cardiac conditions of IgG-injected TAC mice were evident also when we compared LVIDd and 
LVIDs to PBS-injected TAC mice (Fig.29). These results confirmed that the beneficial effects of 
the administration of abatacpet in independent from the immunoglobulin portion of the molecule.  




























Figure 28: Abatacept or human IgG isotype do not affect heart functionality of non-
operated mice. Fractional shortening (%FS) and ejection fraction (%EF) of non-operated 
mice injected with abatacept or human IgG isotype control three times per week for 4 weeks 
did not change compared to sham-operated mice not injected. Values are plotted as mean ± 
SEM (n=3–4). Two-way ANOVA with Bonferroni post-test. 

















































































Figure 29: IgG isotype administration in TAC-operated mice worsen cardiac 
dysfunction. Heart functionality of TAC-operated mice treated with abatacept, PBS or 
human IgG isotype control for 1 week starting 2 days after operation was assessed via 
echocardiography. Fractional shortening (%FS), ejection fraction (%EF), left ventricle 
internal dimension in systole (LVIDs) and left ventricle internal dimension in diastole 
(LVIDd) are plotted as mean ± SEM for each experimental group (n=6-9). Two-way ANOVA 
with Bonferroni post-test; *, p-value <0.05; **, p-value <0.01; ***, p-value <0.001.  
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5.3 Further characterization of the mechanisms of action of abatacept  
 
The mechanisms of function of CTLA4 and abatacept have been extensively studied in many 
contexts, especially for abatacept in RA. Nonetheless we sought to understand how these 
mechanisms may be acting in our treatment of pathological cardiac hypertrophy. 
 
 
5.3.1 Abatacept effects on T cell proliferation and activation 
 
Abatacept binds to CD80/CD86 on APC, hence blocking T cell costimulation. This can lead to T 
cell anergy and cell death.  We first confirmed the abatacept effects on T cell expansion in vitro. 
We cultured total splenocytes, in plates previously coated with anti-CD3e, for 48 hours in the 
presence of 20ng/ml of abatacept or IgG isotype control. We then collected the cells and stained 
for flow cytometry analysis. Anti-CD3 stimulation led to an expansion in the percentage of CD3+ 
T cells. The addition of abatacept, though not its isotype control, to the medium was able to 
reduce this expansion of T cells (Fig.30).  
 
	   104	  
 
 
We then sought to understand whether the effects of abatacept occurred locally at the site of 
pathology and its draining lymph nodes or systemically. We analyzed T cells from TAC-
operated mice treated with abatacept or PBS and or sham-operated mice at 1 week after surgery, 
by flow cytometry for the expression of CD25. We examined T cells harvested from mediastinal 
lymph nodes (which drain the heart), inguinal lymph nodes and spleen (Fig.31). The percentage 
of CD25+ T cells in all these three tissues was significantly reduced in abatacept-injected TAC 
mice, thus suggesting that the suppression of T cell activation occurs systemically. The heart-
infiltrating T cells were too few to enable a robust assessment of CD25 expression levels. As T 
cell suppression will limit their ability to proliferate, the reduced T cell presence in the heart at 4 
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Figure 30: Abatcaept reduces T cell proliferation. Total 
splenocytes of 8 week-old C57BL/6J mice were activated 
with anti-CD3 and cultured with 20µg/ml abatacept or IgG 
isotype control for 72 hours. Splenocytes were stained 
with anti-CD3e and analyzed by FACS. Values are plotted 
as mean ± SEM of 4 independent experiments (n=4). One 
way-ANOVA repeated measurements test with Tukey’s 
post-test. *, p-value <0.05; ***, p-value <0.001. 
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5.3.2 Therapeutic effects of abatacept on PO-induce HF are mediated by the anti-inflammatory 
cytokine IL-10 
 
5.3.2.1 Abatacept administration induces upregulation of IL-10 gene expression 
 
We analyzed the presence of soluble factors in the left ventricle of TAC mice treated with 
abatacept. We analyzed, using qPCR, the gene expression of several cytokines and chemokines 1 
week post-surgery, when therapeutic effects were already evident. In TAC-operated mice treated 
with PBS we found a significant increase of IL-6 expression compared to sham controls, 
confirming the data shown above (Fig.1); we also found a significant increase of IL-6 in 
abatacept-treated mice. Yet abatacept treated TAC-operated mice displayed a significant increase 



























































































Figure 31: Abatacept systemically suppresses T cell activation. Single cell suspensions of (A) 
mediastinal (heart-draining) lymph nodes, inguinal lymph nodes and spleens, 1 week after TAC or 
sham-operation, were stained for flow cytometry analysis. Percentage of CD25+ cells out of 
CD3e+ cells are plotted as mean ± SEM. White bars represent sham mice not injected, grey bars 
represent TAC-operated mice treated with abatacept black bars represent TAC-operated mice 
injected with PBS (n=3). One-way ANOVA with Tukey’s post-test: *, p-value <0.05; **, p-value 
<0.01, ***, p-value<0.001. 
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This was not the case for PBS-treated animals. Given the important immunoregulatory role of 
IL-10, we thus investigated both in-vitro and in-vivo the effects of this cytokine in the 
myocardium and sought to identify the immune population primarily responsible for its 
production.  
 
5.3.2.2 B cells produce IL-10 in response to Abatacept in a T-cell independent manner 
 
We wanted to identify which immune population is the main source of IL-10 in response to 
abatacept. We cultured in total splenocytes vitro on plates coated with anti-CD3e, having added 
20ng/ml of abatacept to the medium. After 48 hours, we analyzed the splenocytes, previously 
stained with antibodies against population-specific surface markers and against IL-10, via flow 
cytometry. Although T cells and macrophages did produce IL-10 in response to abatacept, the 

























































































Figure 32: Il10 expression in left ventricle of TAC-operated mice treated with abatacept is 
upregulated. Gene expression analysis, by real-time qPCR and internally normalized with 18s 
rRNA, of Il6 and Il10 in left ventricle of sham- or TAC-operated mice injected with abatacept or 
PBS 1 week after operation. Bars represent mean ± SEM (n=5, 8) of relative gene expression of 
Il6 and Il10. One-way ANOVA, Dunn’s post-test *, p-value <0.05. 
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In the absence of Abatacept or in the presence of IgG isotype the percentage of IL-10 producing 
B cells was significantly decreased (Fig. 34).  
 




































Figure 33: Abatacept in-vitro induces IL-10 production by B cells. 
Total splenocytes of 8 week-old C57BL/6J mice were activated with 
anti-CD3. Splenocytes were cultured with 20µg/ml abatacept for 72 
hours and stained for flow cytometry analysis. Among IL-10+ cells 
were analyzed the percentage of cells expressing population-specific 
markers (CD19+ B cells, CD11c+ dendritic cells, CD11b+ monocytes 
and myeloid-derived cells, F4/80+ macrophages, CD3e+ T cells, and 
CD3e+ Foxp3+ Treg cells). Values are plotted as mean ± SEM of 3 
independent experiments (n=3). 
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Finally to assess whether the production of IL-10 by B cells was dependent on T cell function, as 
the drug is known to inhibit T cell-dependent B cell functions, we cultured either total 
splenocytes or T cell-depleted splenocytes. The cells were activated with anti-CD3e and LPS, in 
order to be able to activate both T and B cells; abatacept was also present in the medium. We 
assessed the percentage of CD45+ cells producing IL-10 in the different conditions. The absence 
of T cells had no significant effects on the production of IL-10 (Fig.35), suggesting that B cells 
production of IL-10 happens in a T cell-independent manner.  
 
 








































Figure 34: Abatacept in-vitro induces IL-10 
production by B cells. Total splenocytes of 8 
week-old C57BL/6J mice were activated with 
anti-CD3. Splenocytes were cultured with 
20µg/ml abatacept or IgG isotype for 72 hours 
and stained for flow cytometry analysis. IL-10-
producing cells among CD19+ (B cels) were 
analyzed by flow cytometry and plotted as 
mean ± SEM of 3 independent experiments 
(n=3). White bar represents activated 
splenocytes with no addition to the medium, 
grey bar represents activated splenocytes 
cultured with abatacept and black bar 
represents activated splenocytes cultured with 
IgG Isotype. One-way ANOVA, Tukey’s post-
test. *, p-value <0.05; **, p-value <0.01. 
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5.3.2.3 Direct effects of IL-10 and abatacept on cardiomyocytes 
 
In order to verify whether IL-10 had any direct effects on cardiomyocytes, we used an in vitro 
model of cardiac hypertrophy. We isolated neonatal cardiomyocytes and, after an overnight 
starvation, we added PE that, as already mentioned above, is a potent inducer of cardiac 
hypertrophy. We cultured neonatal cardiomyocytes in presence of PE for 48 hours; 4 hours after 
the addition of PE were added either IL-10 or IL-6. At the end of the experiment, cells were 
collected for gene expression analysis of Mhy7, Nppb and Nppa. In the presence PE 














































Figure 35: Abatacept induces IL-10 
production in a T cell-independent manner.  
Total splenocytes or T cell-depleted 
splenocytes were isolated from 8 week-old 
C57BL/6J mice. Cells were activated with 
2µg/ml anti-CD3 and 5 µg/ml of LPS. 
Splenocytes were cultured for 48 hours with or 
without 20µg/ml abatacept. Cells stained and 
analyzed by flow cytometry to assess IL-10 
production. The percentage of CD45+ cells 
producing IL-10 are plotted as mean ± SEM 
(n=3). Black bars represent total splenocytes 
and black bars represent T-cell depleted 
splenocytes. Two-way ANOVA with Bonferroni 
post-test.*, p-value <0.05. 
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cardiomyocytes cultured with PE and IL-10.  The beneficial effects of IL-10 on cardiomyocytes 
have been already shown (Verma	   et al., 2012); these results also support, though not 
conclusively, that IL-10 could have a direct, although limited, inhibitory effect on hypertrophy 
(Fig.36).   
 
We thus wondered whether Abatacept could have a direct effect on cardiomyocytes. We cultured 
neonatal cardiomyocytes with PE for 48 hours in presence of 20µg/ml of Abatacept. After 48 
hours we collected the cells and analyzed the gene expression of hypertrophic genes.  
We observed a significant dowregulation of Mhy7 in cardiomyocytes cultured in presence of PE 
and abatacept compared to cardiomyocytes culture with PE, Nppa and Nppb did not show a 
significant change in gene expression (Fig.37). As this data was inconclusive, we cannot 






Figure 36: Effects of IL-10 on neonatal cardiomyocytes treated with phenylephrine. Gene expression of 
Mhy7, NppA and NppB mRNA relative expression assessed by real-time qPCR in mouse neonatal cardiomyocytes 
48 hours after addition of 100 µM of phenylephrine (PE) and either IL-10 or IL-6. Bars show relative mean ± SEM 
mRNA expression, internally normalized to 18s rRNA expression of 4 independent experiments in triplicates 
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5.3.2.4 IL-10 deficient mice are refractive to abatacept treatment  
 
In order to examine the possible role of IL-10 in the therapeutic effects of abatacept we 
performed TAC or sham operation in C57BL6/J male IL-10 deficient mice (Il10 KO). We 
performed the same therapeutic protocol in IL-10KO mice as in Fig. 16 and we assessed the 
heart functionality by echocardiography. We found a significant decrease in heart functionality 
in Il10 KO mice subjected to TAC and treated with PBS compared to WT TAC-operated mice 
that received the same treatment; Il10 KO sham controls had no significant differences in any 
echocardiographic parameter compared to WT sham controls. Importantly, our data 
demonstrated that the absence of IL-10 completely abolished the therapeutic effects of abatacept. 
Indeed %FS, %EF, LVIDd and LVIDs in Il10 KO mice treated with abatacept did not show any 
improvement compared to PBS injected TAC mice, both WT and Il10 KO (Fig.38). This is 
consistent with previous reports showing that absence of IL-10 in pressure-overload induced 


























































































Figure 37	  Effects of abatacept on neonatal cardiomyocytes treated with phenylephrine. Gene expression of Mhy7, 
NppA and NppB mRNA relative expression assessed by real-time qPCR in mouse neonatal cardiomyocytes 48 hours 
after addition of 100 µM of phenylephrine (PE) and 20µg/ml of abatacept. Bars show relative mean ± SEM mRNA 
expression, internally normalized to 18s rRNA expression of 4 independent experiments in triplicates (n=12). One way-
ANOVA Tukey’s post-test; *, p-value <0.05. 
	   112	  
Thus our results demonstrate that the improvement in cardiac contractility in mice subjected to 
pressure-overload treated with abatacept is mediated by IL-10.  
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Figure 38: Abatacept treatment is ineffective on heart functionality of TAC-operated mice IL-10 
deficient. C57BL6/J male mice WT and IL-10 KO underwent TAC or sham operation and received, 
starting 2 days post-operation, injections of 200µg of abatacept or PBS three times per week, for 4 weeks. 
(A) Fractional shortening (%FS). (B) Ejection fraction (%EF), (C) Left ventricle internal dimension in 
diastole (LVIDd) and (D) Left ventricle internal dimension in systole (LVIDs) were measured by 
echocardiography at baseline, 1 and 4 weeks after operation. Data are plotted as mean ± SEM (n=5–9). 
Two-way ANOVA with Bonferroni post-test. Statistics are indicated as follow: ¢, p-value <0.05 versus TAC 
WT abatacept; ✧ , p-value <0.01 versus TAC WT abatacept; *, p-value <0.001 versus TAC WT abatacept; 
+, p-value <0.05 versus sham not-treated;  , p-value <0.01 versus sham not-treated; #, p-value <0.001 
versus sham not-treated; §, p-value <0.01 versus TAC WT PBS. 
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5.3.2.5 IL-10 is required for the abatacept mediated block of T cell proliferation in the 
myocardium  
 
One of the mechanisms of action of abatacept is to block T cell activation and expansion; as we 
found a significant decrease of T cell presence in the myocardium of TAC-operated mice treated 
with the drug we wondered if this effect was dependent on IL-10. We stained via 
immunohistochemistry with anti-CD3e cardiac sections of Il10 KO mice TAC-operated and 
treated with abatacept or PBS. T cell expansion in the myocardium of Il10 KO TAC-operated 
mice was not inhibited by abatacept administration (Fig.39). This finding suggests that IL-10 is 
required to inhibit T cell expansion; moreover this result also further supports the conclusion that 












Figure 39: Abatacept-mediated inhibition of T cell expansion is IL-10 dependent.   
IL-10KO mice underwent TAC-operation and received abatacept or PBS three times per 
week, starting 2 days after operation. Heart sections of TAC-operated IL-10 KO mice, 4 
weeks after operation, were stained via immunohistochemistry with anti-CD3e. Number of 
CD3e+ per sections is plotted as mean ± SEM (n=2). Unpaired t-test. ns, not significant. 
White bar represents TAC-operated mice injected with abatacept and black bar represents 
TAC-operated mice injected with PBS. Representative images of the staining for CD3e 
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5.3.2.6 IL-10 inhibits cardiomyocyte apoptosis  
 
Cardiomyocytes cell death can occur as consequence of PO-induced cardiac stress (Condorelli et 
al., 1999). We thus wondered if abatacept-treated TAC-operated mice preserved heart 
functionality due to preserved cardiomyocyte viability. We stained heart sections with TUNEL-
staining kit in order to quantify the percentage of apoptotic cardiomyocytes in TAC mice 
(Fig.40). Abatacept-treated WT TAC-operated mice had significantly reduced apoptosis of 
cardiomyocytes, thus potentially explaining the improved heart functionality in this group of 
mice. IL-10 deficiency, as above, eliminated this protective effect of abatacept administration. In 
fact Il10 KO TAC-operated mice that received abatacept had no difference in cardiomyocyte 





























Figure 40: Abatacept inhibition of cardiomyocytes apoptosis is 
mediated by IL-10. C57BL6/J male mice WT and IL-10KO underwent 
TAC operation and received abatacept or PBS three times a week 
starting 2 days after operation. After 4 weeks heart sections were 
stained with TUNEL assay for assessment of cardiomyocytes 
apoptosis. Number of apoptotic cells for each section is plotted as 
mean ± SEM (n=2). White bars represent abatacept-treated TAC-
operated mice and black bars represent PBS-injected TAC-operated 
mice. Two-way ANOVA with Bonferroni post-test; *, p-value <0.05. 
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5.3.2.7 Transfer of WT B cells in IL-10KO TAC mice can restore the therapeutic effects of 
abatacept  
 
Finally we sought to investigate whether the adoptive transfer of IL-10-sufficient immune cells 
was sufficient to restore the abatacept-mediated therapeutic effects. Il10 KO recipients received 
2*106 B cells or 2*106 T cells via intravenal transfer from IL-10 sufficient donors, two days prior 
to TAC operation. WT B and T cells were isolated from C57BL6/J WT male mice age-matched 
with the recipients. T and B cells purity was assessed by flow cytometry and cells were injected 
intravenously. The next day mice were screened for baseline echocardiography analysis and the 
day after TAC was performed. Starting 2 days after the TAC operation, mice received abatacept 
injections three times a week for 1 week (Fig.41). Transfer of WT B cells was sufficient to 
restore the beneficial effects on heart functionality; Il10 KO TAC-operated mice that received 
WT B cells had %FS and %EF values that did not differ from sham controls or from WT TAC-
operated mice that received abatacept. Thus the therapeutic effects that abatacept exerts on heart 
functionality may be dependent on IL-10 production by B cells. 
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Figure 41: Transfer of IL-10 sufficient B cell restores abatacept therapeutic effects in IL-10KO mice. 
IL-10KO mice received wild-type T or B cells prior to TAC-operation and baseline echocardiographic 
screening. TAC-operated mice 2 days post-operation were injected three time per week with 200µg of 
abatacept for 1 week. Heart functionality was assessed via echocardiography and measurement of (A) 
Fractional shortening (%FS) and (B) ejection fraction (%EF). Data are plotted as mean ± SEM for each 
experimental group at all time-points (n=3-7). Two-way ANOVA with Bonferroni post-test. *, statistics for 
IL10 KO TAC abatacept + WT B cells; #, statistics for WT TAC abatacept; §, statistics for sham not treated. 
	   118	  
6. DISCUSSION  
 
Pathological cardiac hypertrophy progression and HF pathogenesis are linked to the 
activation of a cardiac inflammatory response (Hofmann and Frantz, 2013). This inflammatory 
response has been already extensively investigated, especially regarding the involvement of pro-
inflammatory cytokines such IL-6, IL-1b and TNFα (Mann, 2002). Indeed, according to the 
cytokine hypothesis, pro-inflammatory cytokines trigger a cascade of events that lead to HF 
pathogenesis (Seta et al., 1996). Several clinical trials targeting these cytokines were conducted 
with no successful outcome (Mann, 2015). The lack of success of clinical trials targeting pro-
inflammatory cytokines could be related to their redundancy (Yndestad	   et al., 2006). Pro-
inflammatory cytokines activate and sustain the cellular mediators of the immune system. Yet 
many studies have shown that in the pathogenesis of HF cells of both the innate (Epelman et al., 
2014; Kuwahara	   et al., 2012) and the adaptive immune system (Laroumanie	   et al., 2014) are 
involved. Inflammation seems to be involved in many different processes that characterize HF, 
thus the search of a therapeutic target better than individual pro-inflammatory cytokines could be 
very useful. In this study we show that targeting the adaptive immune response has beneficial 
effects on HF development and therapeutic potential, rendering adaptive response mediators a 
potentially utilizable target. 
In order to identify a target for a novel immunotherapeutic approach in HF, we characterized the 
immune response in the gold-standard HF mouse model at different time points after the 
induction of disease via surgical generation of pressure overload. At an early time point (1 week 
post-operation) we identified an increased presence of the innate immune response accompanied 
by M1-related chemokines and cytokines. At a later timepoint, 4 weeks post-operation, we 
identified a decrease in CD11b expression, a marker innate immunity, with a simultaneous 
increase of CD3e expression, a marker for T cell presence. It has been shown that T cells are 
necessary to sustain chronic immune responses (Loke et al., 2007). The increased presence of T 
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cells 4 weeks post-operation in the left ventricle of TAC-operated mice allowed us to speculate 
that T cells could be sustaining the chronic inflammatory response that underlies the 
pathogenesis of HF. The increase in T cells presence was accompanied by a reduction of the 
expression of M1-polarized chemokines and cytokines and the concomitant increase of Th2-
polarized cytokine IL-4 (Zhu, 2015).  
The role of type 2 immune responses in the progression of HF has been already investigated in a 
recent study comparing two strains of mice, C57BL6/J and Balb/c. Balb/c mice, that are more 
prone to type 2 polarized immune responses, develop a more severe form of HF (Yu et al., 
2006). The role of Th2 cells in fibrosis formation has been proposed in many different 
pathological contexts (Wynn, 2004). Thus the simultaneous increase of IL-4 expression and 
upregulation of markers indicative of T cell presence supports the idea that Th2 cells may be 
actively promoting fibrosis formation in TAC-operated mice. Th2-associated cytokines (Zhu and 
Paul, 2010) were absent in the physiological cardiac hypertrophy models that we analyzed. 
Further, fibrosis is a hallmark of pathological cardiac hypertrophy (Daskalopoulos et al., 2016) 
but absent in physiological cardiac hypertrophy, we speculated that the switch towards a Th2 
response in TAC-operated mice could be a driver for fibrosis formation. 
However our speculation are based on gene expression analysis, thus to better understand the 
polarization of the inflammatory response in the myocardium would be necessary to isolate 
cardiac infiltrating T cells. On isolated T cells would be possible to perform ex-vivo analysis of 
cytokine production and also GATA-3 expression should be addressed. 
In addition to Th2 cells, other inflammatory mediators are linked to fibrosis. TGFβ is known to 
activate fibroblasts and to support their differentiation into myoFb (Kong	   et al., 2014). The 
observed increase of TGFβ in the left ventricle of TAC-operated mice may be a reflection of an 
ongoing activation of fibroblasts and the consequent fibrosis formation. This hypothesis is 
further supported by the fact that TGFβ is absent in the left ventricle of AKt-tg mice, which 
develop physiological cardiac hypertrophy and do not develop fibrosis (Condorelli et al., 2002).  
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TAC-operated mice lacking T cells develop a milder form of HF (Laroumanie	   et al., 2014; 
Nevers et al., 2015). Yet, from our data it also seems reasonable to speculate that the role of T 
cells in the progression of HF is not exclusively restricted to their involvement in fibrosis 
formation, as we observed significant differences in aspects unrelated to fibrosis, such as 
cardiomyocyte cell death.  
In the myocardium of TAC-operated mice, T cells are present starting at 1 week post-
operation. T cells were subsequently expanded or further recruited leading to a significant 
increase in their presence by 4 weeks post-operation. The presence of T cells is not restricted to 
HF animal models, thus supporting the clinical relevance to the above findings. We showed that 
T cells are present also in the cardiac biopsies of patients with two different non-immunological 
types of HF. We chose two different types of HF: HF due to a genetic form of dilated 
cardiomyopathy with laminin mutation as well as HF caused by aortic stenosis. These two 
groups of patients share respectively the pathological effects on heart functionality or the initial 
pathological stimulus with TAC-operated mice. Patients with laminin mutation A/C develop HF 
with reduced EF (HFrEF) (Roncarati	  et al., 2013), like the TAC animal model, although differing 
in the initial causes of the disease. On the other hand, patients with aortic stenosis, which 
develop HF (Ross and Braunwald, 1968) with preserved EF (HFpEF) (Drazner, 2011), share the 
same etiology with the TAC-operated mice. The presence of T cells in both groups of patients, 
independently from the etiology and/or the status of their EF, confirms that the involvement of T 
cells is a ubiquitous characteristic in the pathogenesis of HF. Moreover, these findings suggest 
that the manner in which they are recruited and/or expanded in the myocardium is independent 
from the identity of the initial stress stimulus. The connection between T cells and fibrosis was 
also evident in the human biopsies, as T cell presence correlated with collagen deposition. All 
these findings, taken together, are compatible with the hypothesis that T cells are important for 
the pathogenesis of HF.  
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T cells sustain chronic long-lasting immune responses (Loke et al.,2007). Yet even long-
lasting responses have to be physiologically terminated. Treg cells are the natural immune 
regulators of detrimental or unwanted immune responses (Sakaguchi	   et al., 2008). In 
pathological contexts, Treg are recruited to the site of inflammation in the attempt to control and 
block the inflammatory response (Garetto	   et al., 2015); in many cases this recruitment may 
happen too late to successfully control the inflammatory response. This may be the case in the 
myocardium, as our results show. Nevertheless, an artificial boost in Treg numbers has 
beneficial effects, as demonstrated in Treg adoptive transfer studies in HF animal models 
(Kvakan	   et al., 2009; Kanellakis	   et al., 2011). Adoptive cell transfer (ACT) is, indeed, a 
promising approach for many different pathological contexts, yet it currently is an expensive and 
complex therapeutic strategy, in need of substantial development before becoming clinically 
applicable. In order to overcome these intrinsic limitations, we sought a more immediate, less 
demanding and more readily applicable approach that can achieve similar effects as Treg cells 
without the involvement of cell transfer.  
Treg mediate their suppressive effects via different means, already discussed in section 2.3.2. 
These include CTLA4-mediated APC suppression. CTLA4 is a co-inhibitory molecule that 
specifically blocks full activation of T cells, via competitive binding to CD80/CD86, limiting the 
access of CD28 (Frauwirth and Thompson, 2002). CTLA4 has been used in clinic for over 20 
years as a CTLA4-Ig fusion protein (abatacept). Abatacept is an FDA-approved drug for the 
treatment of RA (Moreland et al., 2006). Even though abatacept is a human protein, its efficacy 
in mice has been already demonstrated (Dhirapong	   et al., 2013), rendering it also suitable for 
mouse studies. 
The animal model chosen for this study, the TAC-operated mouse model, is considered the gold 
standard for HF research. The induction of the model requires that the mice undergo a surgical 
procedure. This raises the possible criticism that the inflammatory response identified in the left 
ventricle of TAC-operated mice could be derived from the procedure per se and not related to the 
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cardiac pathogenesis. Yet the sham controls, which undergo the same surgical process with the 
only exception of the absence of final aortic ligation, did show a low –but present- degree of 
inflammation. This demonstrates that the sham group is a valid control for any non-cardiac 
inflammatory component in the TAC model.  
 
We developed two therapeutic protocols for PO-induce HF mice utilizing abatacept. As 
abatacept targets activated T cells and these are detectable in the heart-draining lymph nodes as 
early as 2 days after-operation, in the first therapeutic protocol we started the administration of 
the drug at this timepoint. Although 2 days is a very premature timepoint, the effects of the TAC-
surgery on mice are already detectable via echocardiography, which is a clinically-relevant 
measurement (Souders	  et al., 2012).   
We demonstrated that abatacept delays the progression and reduces the severity of HF in TAC-
operated mice. One of the main effects of PO is the reduced heart functionality and contractility; 
abatacept had significant beneficial effects on several echocardiography parameters used as 
indication of the heart functionality. Significant effects on heart functionality, even if of smaller 
magnitude, were obtained also with administration of abatacept starting 2 weeks after the TAC 
surgery. Other important features of the PO-induced HF reduced by abatacept administration are 
cardiac hypertrophy and “fetal-gene program” reexpression (Dirkx et al., 2013).  
Abatacept, despite being a human fusion protein with a human immunoglobulin Fc domain, did 
not cause any detrimental effect on heart functionality of non-operated mice, thus demonstrating 
that the drug is not immunogenic and despite the presence of a human Fc domain.  This could be 
due to the immunosuppressive effect of CTLA-4. Non-specific immunoglobulin administration 
to HF patients in the past has led to encouraging clinical results (Gullestad	  et al., 2001), through 
an unknown mechanism. This finding could lead to the criticism that the therapeutic effects 
obtained by abatacept administration could be due to a beneficial effect of the Ig-portion of the 
drug.  However the administration of human IgG isotype control to TAC-operated mice 
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drastically worsened the heart functionality. This renders it unlikely that the IgG alone has any 
beneficial effects. This finding further confirmed the validity of choosing PBS administration as 
a more robust and reliable control for the experiments featuring abatacept administration. 
 
We detected a systemic suppression of T cell activation after the administration of 
abatacept in TAC-operated mice. Further, T cell presence in the myocardium was also reduced. 
The decrease of T cell infiltration was accompanied by the reduction of fibrosis, thus further 
supporting the connection between T cells and fibrosis. As abatacept directly binds APC, it is not 
unexpected that the drug also affected macrophage expansion/recruitment and monocyte 
maturation (Wenink	   et al., 2012; Cutolo et al., 2009). Indeed, in the myocardium, abatacept 
inhibited the maturation of monocytes to macrophages and consequently reduced macrophage 
infiltration in the heart.  
Even though the physiological functions of CTLA4 have been already extensively studied, we 
sought to characterize the mechanisms of action of abatacept in HF. Although it has been 
reported that cultured neonatal cardiomyocytes can express CD80 (Nengwen et al., 2014), the 
target of the drug, we did not detect a direct effect on neonatal cardiomyocytes. Yet we cannot 
formally exclude that a direct effect on cardiomyocytes may be contributing to the effects of 
abatacept, as we only assessed gene expression of fetal genes, indicative of the hypertrophic 
state.  
In addition to the systemic suppression of T cell activation, abatacept induced expression of the 
anti-inflammatory and anti-fibrotic cytokine IL-10. As shown in the results section in Fig. 33, 
this was not accompanied by any downregulation of pro-inflammatory cytokine IL-6. IL-6 is 
induced by cardiac stress and it is one of the first cytokines to be produced by cardiomyocytes 
(Souders et al., 2012). IL-6 during the acute phase of cardiac stress has an anti-apoptotic effect 
on cardiomyocytes; yet its chronic activity eventually leads to detrimental effects (Fontes	  et al., 
2015). Moreover with the administration of abatacept we were able to block T cell activation that 
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occurs downstream of IL-6 production, thus the lack of effects on IL-6 expression in TAC-
operated mice abatacept-treated. We found that IL-10 was significantly increased only in TAC-
operated abatacept-treated mice; and not in TAC-operated PBS-treated mice. From this we 
conclude that i) abatacept treatment does not affect the levels of potentially cardiotoxic cytokine 
IL-6; and ii) that the presence of the anti-inflammatory cytokine IL-10 in TAC-operated 
abatacept-treated mice may be counteracting the pro-inflammatory function of IL-6. In other 
words, it is possible that the balance between these two cytokines will determine the overall 
inflammatory response. Another potentially relevant issue is that IL-6 requires to bind to its 
soluble receptor sIL-6R in order to activate pro-fibrotic and pro-hypertrophic responses (Szabo-
Fresnais	  et al., 2010). An assessment of sIL-6R levels in the different treatment groups would 
have been informative. 
From the above results, we thus identified a correlation between the ratio of pro- versus 
anti-inflammatory cytokine expression and the magnitude of the cardiac dysfunction. In order to 
quantify this correlation, we calculated two indexes, one indicative of inflammation and one 
indicative of heart dysfunction. The inflammation index was calculated as the mRNA level of the 
pro-inflammatory cytokine IL-6 divided by mRNA level of the anti-inflammatory cytokine IL-
10. The heart dysfunction index (HDI) was calculated as (-1) x (% fractional shortening), for all 
mouse models analyzed in this study and normalized to their matching control group.  
These two indexes show that improvement of heart functionality after abatacept administration is 
accompanied by decreased inflammation. Not only does this give insights on the mechanism of 
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Figure 42: Realtionship between inflammation index and heart dysfucntion. Heart dysfunction index (HDI) plotted 
on the y axis versus an inflammation index on the x axis. Each point represents data from one mouse. Larger points 
indicate the mean of each group and the shaded ellipses represent one standard deviation from the mean. HDI values were 
internally normalized. Healthy refers to sham-operated control (PBS-treated) mice. TAC model of HF refers to TAC-
operated control (PBS-treated) mice. TAC model of HF abatacept –treated refers to TAC-operated treated with abatacept 
three times per week starting 2 days post-operation. All groups are represented at 1 (above graph) and 4 weeks (bottom 
graph) post-operation. The normalization of the HDI for each mouse was calculated with the following formula: [[HDI of 
sample − mean HDI of matching control] / mean HDI of matching control]. The following groups were used as matching 
controls for normalization: for TAC-operated mice at 1 or 4 weeks post-operation: sham-operated mice prior to operation 
(basal reading); for healthy mice (sham-operated): sham operated prior to operation (basal reading).  
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Compatible with the above results, TAC-operated IL-10-deficient mice were refractive to 
the treatment. The cardio-protective effects of IL-10 have been previously demonstrated (Verma	  
et al., 2012) rendering further support to the interpretation that abatacept exerts its therapeutic 
functions on the myocardium throughout this cytokine. Moreover, for the same reasons, the 
reduced heart functionality in TAC-operated IL-10-deficient mice treated with PBS is not 
surprising.  
Abatacept targets APC by binding to CD80/CD86, yet it has been reported to not have 
any direct effects on DC phenotype or gene expression (Carman	  et al., 2009), while it has been 
shown to directly modulate macrophages and B cells (Mihara et al., 2000; Cutolo et al., 2009). 
Indeed B cells are the main source of IL-10 in response to abatacept administration. We were 
able to detect a low-level production of IL-10 from T cells and Treg after abatacept 
administration in vitro. Nonetheless, only the transfer of IL-10-sufficient B cells, not IL-10-
sufficient T cells, prior to treatment, in TAC-operated mice lacking IL-10 was able to restore the 
therapeutic effects of abatacept on cardiac functionality.  
Abatacept is known to exert its effects exclusively on T cell-dependent APC functions 
(Wenink	  et al., 2012; Mihara	  et al., 2000). Yet, in vitro IL-10 production by B cells in response 
to the drug occured in a T cell-independent manner. We can thus speculate that abatacept, via the 
binding of CD80/CD86 on B cells, may possibly activate intracellular signaling that induces IL-
10 production in B cells, independently from T cell presence.  
Another way of action of abatacept is through the induction of Treg expansion (Ko et al., 
2010). However, we did not observe an increase of Treg in the left ventricle of TAC-mice treated 
with the drug, thus –at least in our system- there is no concrete evidence for such an effect. 
In conclusion, our results show, as a consequence of abatacept treatment, IL-10 blocks 
the deterioration of heart functionality in TAC-operated mice. In response to abatacept 
administration, we detected a reduction of T cell expansion and macrophage 
recruitment/expansion. This may lead to reduced fibrosis and cardiomyocyte apoptosis, enabling 
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the preservation of heart functionality. 
 We have summarized our findings in a scheme (Fig. 43) depicting the effects of abatacept 
on the myocardium. In response to pressure overload-induced stress signals in the myocardium, 
an inflammatory response is generated, featuring increased pro-inflammatory cytokines. This 
inflammatory response activates and recruits macrophages. Macrophages, and B cells, acting as 
APC, fully activate T cells via costimulation. The T cells may then become responsible for the 
maintenance of the long-lasting response that ensues (Loke	  et al., 2007). As a consequence of 
this immune cell infiltration, fibrosis formation and increased cardiomyocyte cell death occurs, 
leading to reduced heart functionality. Abatacept administration enabled us to control this 
inflammatory response and thus to inhibit these three hallmarks of cardiac pathology, by 
impeding T cell costimulation. Moreover, abatacept induces an increased production of IL-10, 
mainly by B cells, which further blocks T cell expansion. IL-10 production by B cells is essential 
for the therapeutic effects of abatacept in the myocardium and it occurs in a T cell-independent 
manner. As a caveat, it is important to stress that this is not the only way to modulate HF; rather 
this therapeutic approach could be integrated with other therapeutic strategies. The main 
advantage of our approach is that abatacept is an FDA-approved drug and which been in clinical 
practice for more than 10 years (Moreland	  et al., 2006). Thus the adverse effects of the drug are 
limited, and its toxicological profile is well-studied. Hence, our proof-of-principle approach may 
have substantial translational potential. 
 
 
	   128	  
 
Figure 43: Summary of abatacept administration therapeutic effects in PO-induced HF. During pathological cardiac 
hypertrophy increase of pro-inflammatory cytokines that recruit and activate macrophages and B cells, which can act as antigen-
presenting cells (APCs). T cells receive costimulation from APC via CD28 binding to CD80/CD86 and increase CD25 
expression. Fully activated T cells maintain chronic inflammatory response in the myocardium responsible for increased 
fibrosis, apoptosis and decreased heart functionality.  Administration of abatacept, which bind to CD80/CD86 expressed on 
APCs, blocks T cell costimulation thus reduces their activation and expansion. Direct effect on macrophages reduces their 
maturation and on B cells induces IL-10 production. As result of the above apoptosis and fibrosis are reduced whilst heart 
functionality is maintained.    
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7. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The results presented in this study demonstrate that abatacept, an FDA-approved drug, 
that block T cell costimulation can significantly reduce the severity and delay the progression of 
HF in a PO-induced HF mouse model. These results taken together underline the importance of 
adaptive immune responses in the pathogenesis of cardiac hypertrophy and HF progression. The 
activation of adaptive immunity in response to cardiac stress signals could be an unwanted 
consequence of the immune system’s inability to distinguish between pathogen-induced signals 
and pressure-overload induced cardiac injury. Indeed, it will be interesting to deepen our 
understanding in the future of the exact nature of the triggers of adaptive immune activation in 
HF.  Above all it is necessary to assess the source of the pro-inflammatory cytokines and 
chemokines expressed in the left ventricle of TAC-operated mice. Although it has been reported 
in literature (Souders et al., 2012) and suggested from our in-vitro experiments on neonatal 
cardiomyocytes (Section 5.1.3, figure 7) that cardiomyocytes produce pro-inflammatory 
cytokines, it is necessary in the future perform gene expression analysis on different cell 
populations isolated form TAC-operated mice. It is essential in fact to notice that in this study we 
did not analyzed the involvement of the stromal component and of fibroblasts, which are the 
most abundant cell component of the myocardium (Fujiu and Nagai, 2013). Since abatacept 
administration reduces fibrosis formation in TAC-operated mice we hypothesized that the 
reduction of fibrosis is dependent on T cell activation, however it is necessary unveil the effects 
on fibroblasts.   
 
Several important further analyses would be needed before usage of this therapy for HF 
patients in the clinic can be proposed. Although the TAC-operated mouse model is the gold-
standard experimental model for HF studies, it still presents experimental limitations, as it does 
not completely reflect the pathogenesis of some forms of HF. Yet, our data show that T cells are 
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present in the myocardium of patients with different types of HF: patients with laminin A/C 
mutations, developing HFrEF as well as patients with aortic stenosis, mostly developing HFpEF. 
The TAC-operated mouse model displays HFrEF, thus resembling the symptoms of patients with 
laminin mutations. On the other hand, the TAC-operated mouse model is driven by the same 
mechanistic cause as that found in patients with aortic stenosis. The biggest limitation of the 
mouse model used in this study is that even if it resembles the human pathological for what 
concerns the triggering pathological cardiac hypertrophy, it does not match the clinical 
symptoms. Our therapeutic approach should be evaluated in an experimental model of HFpEF in 
order to add further support to its eventual applicability in the clinic. Unfortunately, currently 
such an experimental model has not yet been fully validated. Clinical trials in humans would 
have to be performed in order to validate the clinical applicability and efficacy of the approach. 
It is hoped that such efforts may aid in bringing a novel and greatly needed therapeutic solution 
to the urgent clinical burden of HF. 
Finally, despites the further analyses above mentioned, this study highlights the 
importance of finding new pathological applications for existing drugs. Indeed, as for other 
pathological contexts (Marschallinger	  et al., 2015), validated immune-mediated therapy reagents 
could be suitable for novel therapeutic applications in chronic pathologies where inflammation 
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